<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003575.pub6" GROUP_ID="IBD" ID="827401110311570990" MERGED_FROM="" MODIFIED="2017-11-08 19:15:57 +0000" MODIFIED_BY="John MacDonald" REVIEW_NO="41" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2017-11-08 19:15:57 +0000" MODIFIED_BY="John MacDonald">
<TITLE>Interventions for treating collagenous colitis</TITLE>
<CONTACT MODIFIED="2017-11-08 19:15:57 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="8955" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John WD</FIRST_NAME><LAST_NAME>McDonald</LAST_NAME><SUFFIX>MD PhD FRCPC</SUFFIX><POSITION>Editor, IBD/FBD Group</POSITION><EMAIL_1>john.mcdonald@robartsinc.com</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 663 3533</PHONE_1><PHONE_2>+1 519 931 5280</PHONE_2><FAX_1>+1 519 663 3807</FAX_1><FAX_2>+1 519 931 5705</FAX_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-11-08 19:15:57 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="z1611021600507491620145363552535" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tahir</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Kafil</LAST_NAME><EMAIL_1>tahirkafil@outlook.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="z1607251411590401623801479701474" ROLE="AUTHOR"><FIRST_NAME>Tran</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Nguyen</LAST_NAME><EMAIL_1>tran.nguyen@robartsinc.com</EMAIL_1><EMAIL_2>cochraneibdreviewgroup@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="z1506111342364952331166491859006" ROLE="AUTHOR"><FIRST_NAME>Petrease</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Patton</LAST_NAME><EMAIL_1>p.h.patton@gmail.com</EMAIL_1><EMAIL_2>ppatton2017@meds.uwo.ca</EMAIL_2><ADDRESS><DEPARTMENT>Schulich School of Medicine &amp; Dentistry</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="9897" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>MacDonald</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>john.macdonald@robartsinc.com</EMAIL_1><EMAIL_2>jmacdon1@uwo.ca</EMAIL_2><URL>http://ibd.cochrane.org/</URL><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><ZIP>N6A 5B6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 226 270 7868</PHONE_1></ADDRESS></PERSON><PERSON ID="14344" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nilesh</FIRST_NAME><LAST_NAME>Chande</LAST_NAME><EMAIL_1>nilesh.chande@lhsc.on.ca</EMAIL_1><EMAIL_2>nchande2@uwo.ca</EMAIL_2><ADDRESS><ORGANISATION>London Health Sciences Centre - Victoria Hospital</ORGANISATION><ADDRESS_1>Room E6-321A</ADDRESS_1><ADDRESS_2>800 Commissioners Road East</ADDRESS_2><CITY>London</CITY><ZIP>N6A 5W9</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 667 6582</PHONE_1><FAX_1>+1 519 667 6820</FAX_1></ADDRESS></PERSON><PERSON ID="8955" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John WD</FIRST_NAME><LAST_NAME>McDonald</LAST_NAME><SUFFIX>MD PhD FRCPC</SUFFIX><POSITION>Editor, IBD/FBD Group</POSITION><EMAIL_1>john.mcdonald@robartsinc.com</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 663 3533</PHONE_1><PHONE_2>+1 519 931 5280</PHONE_2><FAX_1>+1 519 663 3807</FAX_1><FAX_2>+1 519 931 5705</FAX_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-11-08 11:45:27 -0500" MODIFIED_BY="John K MacDonald">
<UP_TO_DATE>
<DATE DAY="7" MONTH="11" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="11" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-11-08 12:58:07 -0500" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-08 12:58:07 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="7" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>New literature search performed on 7 November 2016. Two new studies were added. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-11-08 12:58:06 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="7" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>Updated review with changes to conclusions and new authors </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-11-08 09:18:13 -0500" MODIFIED_BY="John K MacDonald"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-11-08 13:58:41 -0500" MODIFIED_BY="John K MacDonald">
<SUMMARY MODIFIED="2017-11-08 13:54:13 -0500" MODIFIED_BY="John K MacDonald">
<TITLE MODIFIED="2008-05-06 10:32:56 -0400" MODIFIED_BY="John K MacDonald">Treatments for collagenous colitis</TITLE>
<SUMMARY_BODY MODIFIED="2017-11-08 13:54:13 -0500" MODIFIED_BY="John K MacDonald">
<P>
<B>What is collagenous colitis?</B> </P>
<P>Collagenous colitis is a type of microscopic colitis, a condition characterized by chronic watery non-bloody diarrhea. People with collagenous colitis have a normal appearing bowel when assessed by an endoscope (a camera used to look at the bowel); but have microscopic inflammation of the bowel when assessed by a biopsy (a tissue sample taken during endoscopy). The cause of this disorder is unknown. </P>
<P>
<B>What treatments have been tried for lymphocytic colitis?</B> </P>
<P>Budesonide, mesalamine, cholestyramine, <I>Boswellia serrata</I> extract, probiotics, prednisolone and Pepto-Bismol® have been studied as treatment for collagenous colitis. Budesonide is an immunosuppressive steroid drug that is quickly metabolized by the liver resulting in reduced steroid-related side-effects. Prednisolone is a steroid drug used to treat inflammation. Mesalamine (also known as 5-ASA) is an anti-inflammatory drug. Cholestyramine is a drug that helps the body remove bile acids. Pepto-Bismol®, is an antacid medication used to treat discomforts of the stomach and gastrointestinal tract. <I>Boswellia serrata</I> extract is a herbal extract. Probiotics are found in yogurt or dietary supplements and contain potentially beneficial bacteria or yeast. </P>
<P>
<B>What did the researchers investigate?</B> </P>
<P>The researchers investigated whether these treatments improve symptoms (e.g. diarrhea) or microscopic inflammation of collagenous colitis and whether any side effects (harms) result from treatment. The researchers searched the medical literature extensively up to 7 November 2016.</P>
<P>
<B>What did the researchers find?</B> </P>
<P>Twelve studies (476 participants) were identified. Four studies were high quality. One study assessing mesalamine and cholestyramine was judged to be low quality and the other studies were judged to be of unclear quality due to poor reporting of methods. </P>
<P>Diarrhea resolved in 100% (4/4) of Pepto-Bismol® (nine 262 mg tablets daily for 8 weeks) participants compared to 0% (0/5) of placebo participants (1 study; very low quality evidence). Diarrhea resolved in 44% (7/16) of <I>Boswellia serrata</I> participants (three 400 mg/day capsules for 8 weeks) compared to 27% (4/15) of placebo participants (1 study; low-quality evidence). Diarrhea resolved in 80% (24/30) of budesonide participants compared to 44% (11/25) of mesalamine participants (1 study; low-quality evidence). There was no difference between the two treatments with respect to side effects. Diarrhea resolved in 44% (11/25) of mesalamine (3 g/day) participants compared to 59% (22/37) of placebo participants (1 study; low-quality evidence). There was no difference between the two treatments with respect to side effects. Diarrhea resolved in 63% (5/8) of prednisolone (50 mg/day for 2 weeks) participants compared to 0% (0/3) of placebo participants (1 study, low-quality evidence). Diarrhea resolved in 29% (6/21) of participants who received probiotics (2 capsules containing probiotics twice daily for 12 weeks) compared to 13% (1/8) of placebo participants (1 study, very low-quality evidence). Diarrhea resolved in 73% (8/11) of mesalamine (800 mg three times daily) participants compared to 100% (12/12) of mesalamine + cholestyramine participants (4 g daily) (1 study, very low-quality evidence). Diarrhea resolved in 81% (38/47) of budesonide (9 mg daily for 6-8 weeks) participants compared to 17% (8/47) of placebo participants (3 studies; low-quality evidence). Improvement in microscopic inflammation occurred in 72% (34/47) of budesonide participants compared to 17% (8/47) placebo participants (low-quality evidence). Resolution of diarrhea was maintained over 6 months in 68% (57/84) of budesonide participants compared to 20% (18/88) of placebo participants (3 studies, low-quality evidence). Improvement in microscopic inflammation was maintained in 48% (19/40) of budesonide participants compared to 15% (6/40) of placebo participants (2 studies; very low-quality evidence). No difference was found between budesonide and placebo for side effects (low-quality evidence) or serious side effects (very low-quality evidence). Side effects reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, excessive sweating and headache. Side effects reported in the mesalamine studies included nausea and skin rash. Side effects in the prednisolone study included abdominal pain, headache, sleep disturbance, mood change and weight gain. </P>
<P>In conclusion, low quality evidence suggests that budesonide may be an effective therapy for active and inactive collagenous colitis. Due to small sample sizes and low study quality we are uncertain about the benefits and harms of therapy with Pepto-Bismol®, <I>Boswellia serrata</I> extract, mesalamine with or without cholestramine, prednisolone and probiotics. These agents and other therapies require further study. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-11-08 13:54:00 -0500" MODIFIED_BY="John K MacDonald">
<ABS_BACKGROUND MODIFIED="2017-11-08 13:09:32 -0500" MODIFIED_BY="John K MacDonald">
<P>Collagenous colitis is a cause of chronic diarrhea. This updated review was performed to identify therapies for collagenous colitis that have been assessed in randomized controlled trials (RCTs).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-11-08 13:16:16 -0500" MODIFIED_BY="John K MacDonald">
<P>The primary objective was to assess the benefits and harms of treatments for collagenous colitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-02-22 10:02:56 -0500" MODIFIED_BY="John K MacDonald">
<P>We searched CENTRAL, the Cochrane IBD Group Specialized Register, MEDLINE and EMBASE from inception to 7 November 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-11-08 13:10:02 -0500" MODIFIED_BY="John K MacDonald">
<P>We included RCTs comparing a therapy with placebo or active comparator for the treatment of active or quiescent collagenous colitis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-11-08 13:08:43 -0500" MODIFIED_BY="John K MacDonald">
<P>Data were independently extracted by two authors. The primary outcome was clinical response or maintenance of response as defined by the included studies. Secondary outcome measures included histological response, quality of life and the occurrence of adverse events. Risk ratios (RR) and 95% confidence intervals (CI) were calculated for dichotomous outcomes. The Cochrane risk of bias tool was used to assess bias. The overall quality of the evidence was assessed using the GRADE criteria. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-11-08 13:54:00 -0500" MODIFIED_BY="John K MacDonald">
<P>Twelve RCTs (476 participants) were included. These studies assessed bismuth subsalicylate, <I>Boswellia serrata</I> extract, mesalamine, cholestyramine, probiotics, prednisolone and budesonide therapy. Four studies were low risk of bias. One study assessing mesalamine and cholestyramine was judged to be high risk of bias due to no blinding. The other studies had an unclear risk of bias for random sequence generation (five studies) allocation concealment (six studies), blinding (one study), incomplete outcome data (one study) and selective outcome reporting (one study). Clinical response occurred in 100% (4/4) of patients who received bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks) compared to 0% (0/5) of patients who received placebo (1 study; 9 participants; RR 10.80, 95% CI 0.75 to 155.93; GRADE = very low). Clinical response occurred in 44% (7/16) of patients who received <I>Boswellia serrata</I> extract (three 400 mg/day capsules for 8 weeks) compared to 27% (4/15) of patients who received placebo (1 study; 31 participants; RR 1.64, 95% CI 0.60 to 4.49; GRADE = low). Clinical response occurred in 80% (24/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study; 55 participants; RR 1.82, 95% CI 1.13 to 2.93; GRADE = low). Histological response was observed in 87% (26/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study, 55 participants; RR 1.97, 95% CI 1.24 to 3.13; GRADE = low). There was no difference between the two treatments with respect to adverse events (RR 0.69, 95% CI 0.43 to 1.10; GRADE = low), withdrawals due to adverse events (RR 0.09, 95% CI 0.01 to 1.65; GRADE = low) and serious adverse events (RR 0.12, 95% CI 0.01 to 2.21; GRADE = low). Clinical response occurred in 44% (11/25) of mesalamine patients (3 g/day) compared to 59% (22/37) of placebo patients (1 study; 62 participants; RR 0.74, 95% CI 0.44 to 1.24; GRADE = low). Histological response was observed in 44% (11/25) and 51% (19/37) of patients receiving mesalamine and placebo, respectively (1 study; 62 participants; RR 0.86, 95% CI 0.50 to 1.47; GRADE = low). There was no difference between the two treatments with respect to adverse events (RR 1.26, 95% CI 0.84 to 1.88; GRADE = low), withdrawals due to adverse events (RR 5.92, 95% CI 0.70 to 49.90; GRADE = low) and serious adverse events (RR 4.44, 95% CI 0.49 to 40.29; GRADE = low). Clinical response occurred in 63% (5/8) of prednisolone (50 mg/day for 2 weeks) patients compared to 0% (0/3) of placebo patients (1 study, 11 participants; RR 4.89, 95% CI 0.35 to 68.83; GRADE = very low). Clinical response occurred in 29% (6/21) of patients who received probiotics (2 capsules containing 0.5 x 10<SUP>10</SUP> CFU each of <I>L. acidophilus LA-5</I> and <I>B. animalis subsp. lactis</I> strain BB-12 twice daily for 12 weeks) compared to 13% (1/8) of placebo patients (1 study, 29 participants, RR 2.29, 95% CI 0.32 to 16.13; GRADE = very low). Clinical response occurred in 73% (8/11) of patients who received mesalamine (800 mg three times daily) compared to 100% (12/12) of patients who received mesalamine + cholestyramine (4 g daily) (1 study, 23 participants; RR 0.74, 95% CI 0.50 to 1.08; GRADE = very low). Clinical response occurred in 81% (38/47) of patients who received budesonide (9 mg daily in a tapering schedule for 6 to 8 weeks) compared to 17% (8/47) of placebo patients (3 studies; 94 participants; RR 4.56, 95% CI 2.43 to 8.55; GRADE = low). Histological response was higher in budesonide participants (72%, 34/47) compared to placebo (17%, 8/47) (RR 4.15, 95% CI 2.25 to 7.66; GRADE = low). Clinical response was maintained in 68% (57/84) of budesonide patients compared to 20% (18/88) of placebo patients (3 studies, 172 participants, RR 3.30 95% CI 2.13 to 5.09; GRADE = low). Histological response was maintained in 48% (19/40) of budesonide patients compared to 15% (6/40) of placebo patients (2 studies; 80 participants; RR 3.17, 95% CI 1.44 to 6.95; GRADE = very low). No difference was found between budesonide and placebo for adverse events (5 studies; 290 participants; RR 1.18, o95% CI 0.92 to 1.51; GRADE = low), withdrawals due to adverse events (5 studies, 290 participants; RR 0.97, 95% CI 0.43 to 2.17; GRADE = very low) or serious adverse events (4 studies, 175 participants; RR 1.11, 95% CI 0.15 to 8.01; GRADE = very low). Adverse effects reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, excessive sweating and headache. Adverse effects reported in the mesalamine studies included nausea and skin rash. Adverse effects in the prednisolone study included abdominal pain, headache, sleep disturbance, mood change and weight gain. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-11-08 12:30:48 -0500" MODIFIED_BY="John K MacDonald">
<P>Low quality evidence suggests that budesonide may be effective for inducing and maintaining clinical and histological response in patients with collagenous colitis. We are uncertain about the benefits and harms of therapy with bismuth subsalicylate, <I>Boswellia serrata</I> extract, mesalamine with or without cholestramine, prednisolone and probiotics. These agents and other therapies require further study.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-11-08 13:58:41 -0500" MODIFIED_BY="John K MacDonald">
<BACKGROUND MODIFIED="2017-11-08 12:45:12 -0500" MODIFIED_BY="John K MacDonald">
<P>Collagenous colitis is a cause of chronic diarrhea. Together with lymphocytic colitis, it falls under the more general heading 'microscopic colitis', an appropriately descriptive name given the normal radiologic and colonoscopic appearance but abnormal histologic appearance of the colon in these disorders. The etiology and pathogenesis of collagenous colitis are unknown. Treatment has been based mainly on anecdotal evidence. The literature includes uncontrolled reports on treatment of one or both of these disorders with traditional corticosteroids (oral, intravenous, or topical), budesonide, bismuth subsalicylate, 5-ASA compounds, azathioprine/6-mercaptopurine, methotrexate, cyclosporine, probiotics, antibiotics, cholestyramine/colestipol, octreotide, antihistamines, ketotifen, verapamil, pentoxifylline, antidiarrheal agents, bulking agents, spasmolytics, dietary modification, and surgery (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). It is difficult to draw firm conclusions about treatment efficacy from these uncontrolled studies. Randomized controlled studies provide better evidence for the effectiveness of therapeutic interventions in patients with collagenous colitis. A systematic review of the available randomized controlled studies was undertaken to evaluate the available evidence. This review is an update of a previously published Cochrane systematic review (<LINK REF="REF-Chande-2002" TYPE="REFERENCE">Chande 2002</LINK>; <LINK REF="REF-Chande-2003a" TYPE="REFERENCE">Chande 2003a</LINK>; <LINK REF="REF-Chande-2003b" TYPE="REFERENCE">Chande 2003b</LINK>; <LINK REF="REF-Chande-2004a" TYPE="REFERENCE">Chande 2004a</LINK>; <LINK REF="REF-Chande-2004b" TYPE="REFERENCE">Chande 2004b</LINK>; <LINK REF="REF-Chande-2005" TYPE="REFERENCE">Chande 2005</LINK>; <LINK REF="REF-Chande-2006" TYPE="REFERENCE">Chande 2006</LINK>; <LINK REF="REF-Chande-2008" TYPE="REFERENCE">Chande 2008</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-11-08 12:45:13 -0500" MODIFIED_BY="John K MacDonald">
<P>The primary objective was to assess the benefits and harms of treatments for patients with collagenous colitis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-11-08 13:54:37 -0500" MODIFIED_BY="John K MacDonald">
<SELECTION_CRITERIA MODIFIED="2017-11-08 12:45:14 -0500" MODIFIED_BY="John K MacDonald">
<CRIT_STUDIES MODIFIED="2017-07-05 13:34:34 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized controlled trials were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-11-08 12:45:14 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients with biopsy-proven collagenous colitis were considered for inclusion. For trials assessing induction of response patients were required to have clinically active collagenous colitis at the time of randomization. For trials assessing maintenance of response symptoms needed to be quiescent at the time of randomization. Patients with a diagnosis of microscopic colitis were included only if biopsies revealed a thickened subepithelial collagen band.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-11-08 12:45:14 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized trials comparing a medical therapy to placebo or an active comparator for treatment of collagenous colitis were considered for inclusion in the review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-05-18 15:38:41 -0400" MODIFIED_BY="Tran M Nguyen">
<P>For studies assessing treatment of active disease, the primary outcome measure was the number of patients with a clinical response expressed as a percentage of patients randomized (intention-to-treat analysis). Clinical response was defined as decreased fecal frequency or stool weight or both. Secondary outcome measures included histological response, effect on quality of life as measured by a validated instrument, and occurrence of adverse events.</P>
<P>For studies assessing maintenance of response, the primary outcome measure was the number of patients with a maintained clinical response expressed as a percentage of patients randomized (intention-to-treat analysis). Clinical response was defined as a lack of clinical relapse. Secondary outcome measures included maintenance of histological response, time to relapse, effect on quality of life as measured by a validated instrument, and occurrence of adverse events.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-11-08 12:45:14 -0500" MODIFIED_BY="John K MacDonald">
<P/>
<P>We searched the following databases from inception to 7 November 2016:</P>
<OL>
<LI>MEDLINE (Ovid);</LI>
<LI>EMBASE (Ovid);</LI>
<LI>Cochrane Central Register of Controlled Trials; and</LI>
<LI>The Cochrane IBD Inflammatory Bowel Disease and Functional Bowel Disorders Review Group Specialized Trials Register.</LI>
</OL>
<P>The electronic search strategies are described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-11-08 13:54:37 -0500" MODIFIED_BY="John K MacDonald">
<P>All publications identified by the search strategy were assessed independently by two authors (TSK and TMN or PHP), and relevant studies were selected according to the inclusion criteria. Any disagreement among authors was resolved by consensus or by consulting a third author (JKM). Studies published in abstract form only were included only if the authors could be contacted for further information.</P>
<P>Two authors (TSK and TMN or PHP) independently extracted data using a data extraction form. Any disagreement among authors was resolved by consensus or by consulting a third author (JKM).</P>
<P>Outcome data were extracted from the original research articles and converted into 2x2 tables. In cross-over studies, only data from the first arm were included. All data were analyzed on an intention-to-treat basis, and treated dichotomously. Data were combined for analysis if they assessed the same treatments with the same comparator, and had similar definitions of outcome measures (determined by consensus). We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for dichotomous outcomes .</P>
<P/>
<P>Other information extracted from the studies included:</P>
<P>a. Study characteristics and design;<BR/>b. Characteristics of patients;<BR/>c. Inclusion and exclusion criteria;<BR/>d. Interventions; and<BR/>e. Outcomes scoring methods.</P>
<P>The presence of heterogeneity among studies was assessed using the Chi<SUP>2</SUP>test. As the Chi<SUP>2</SUP> chi-square test has low power in the situation of a meta-analysis, when trials have small sample size or are few in number, a P value of 0.10 was regarded as statistically significant. </P>
<P>Two authors (TSK and TMN or PHP) independently assessed study quality using the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), which assesses:</P>
<OL>
<LI>Random sequence generation;</LI>
<LI>Allocation concealment;</LI>
<LI>Blinding of participants, personnel and assessment of outcome;</LI>
<LI>Incomplete outcome data;</LI>
<LI>Selective reporting; and</LI>
<LI>Other biases.</LI>
</OL>
<P>Each category was evaluated as low, high or unclear risk of bias and support for each judgment justification was provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section. Any disagreement among authors was resolved by consensus or by consulting a third author (JKM).</P>
<P>
<B>GRADE Analysis</B>
</P>
<P>The overall quality of the evidence supporting the outcomes reported in this review was evaluated using the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). In this approach outcome data were rated high, moderate, low or very low. Outcome data from randomized controlled trials begins as high quality but it can be downgraded based on a number of criteria. These criteria are:</P>
<OL>
<LI>Risk of bias in the included studies;</LI>
<LI>Indirect evidence (by comparison, population, setting);</LI>
<LI>Inconsistency (unexplained heterogeneity);</LI>
<LI>Imprecise results (i.e. sparse data, wide confidence intervals); and</LI>
<LI>Likelihood of publication bias.</LI>
</OL>
<P>These ratings correspond to various levels of confidence:</P>
<UL>
<LI>High quality - more research is not likely to alter the finding;</LI>
<LI>Moderate quality - more research is likely to alter the finding;</LI>
<LI>Low quality - more research is very likely to alter the finding; or</LI>
<LI>Very low quality - we are very uncertain about this finding (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>).</LI>
</UL>
<P>All data were analyzed on an intention-to-treat basis, and treated dichotomously. Data were combined for analysis if the studies assessed the same treatments with the same comparator, and had similar definitions of outcome measures (determined by consensus). For pooled data, summary test statistics were derived using the RR and corresponding 95% confidence interval. A fixed-effect model was used for pooling of data when statistical heterogeneity was not present. When statistical heterogeneity was present a random-effects model was used. If heterogeneity was substantially high (I<SUP>2</SUP> &gt; 75%) and a single study that was causing the heterogeneity was identified, it was excluded from pooled meta-analysis.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-11-08 13:58:41 -0500" MODIFIED_BY="John K MacDonald">
<STUDY_DESCRIPTION MODIFIED="2017-11-08 13:58:41 -0500" MODIFIED_BY="John K MacDonald">
<P/>
<P/>
<SEARCH_RESULTS MODIFIED="2017-11-08 12:46:04 -0500" MODIFIED_BY="John K MacDonald">
<P>A literature search conducted on 7 November 2016 identified 390 studies. After duplicates were removed a total of 204 studies remained for review of titles and abstracts. Thirty-nine reports of interventions for collagenous colitis were selected for full text review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Six studies were excluded for not meeting the inclusion criteria (See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). The remaining 33 reports from 12 studies were evaluated for qualitative analysis and 13 studies underwent quantitative analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-11-08 13:58:41 -0500" MODIFIED_BY="John K MacDonald">
<P>Twelve randomized controlled trials (476 participants with collagenous colitis) that met the inclusion criteria were identified (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>; <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>). Eight of these studies assessed induction of clinical response by comparing an active treatment to placebo: <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> studied bismuth subsalicylate (published in abstract form only); <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK> studied <I>Boswellia serrata</I> extract; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK> studied probiotics; <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK> studied prednisolone; <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>, <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>, and <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK> studied budesonide. <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> randomized patients with active disease to three treatment arms: budesonide, mesalamine and placebo. One study (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>) compared mesalamine to mesalamine plus cholestyramine for inducing clinical response in patients with active disease. Three studies compared budesonide to placebo for maintenance of clinical response in patients with quiescent disease (<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>, <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>
<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK> performed a prospective, double-blind, placebo-controlled clinical trial at Belgian universities and peripheral centres to determine the clinical and histological response of collagenous colitis to budesonide versus placebo over an 8 week trial, with an 8 week treatment-free follow-up for responders or an 8 week open-label budesonide trial for non-responders. Twenty-eight patients with established collagenous colitis and chronic symptoms for at least eight weeks were randomized to budesonide 9 mg/day (3 Budenofalk 3 mg capsules with pH-modified release; n =14) or placebo (n = 14). With the exception of controlled gastroesophageal reflux disease and celiac disease on a long-term gluten-free diet, patients with significant gastrointestinal disease were excluded. All other medications were halted and given an appropriate wash out time. After eight weeks, patients were evaluated clinically and histologically for response (clinical: reduction of stool frequency in last week of treatment by at least 50%; histological: statistically significant reduction of the infiltrate in the lamina propria or a significant reduction in the mean thickness of the collagen band). Secondary outcomes included abdominal pain, stool consistency score, patient's general well-being, time to remission, safety, and long-term clinical effects of budesonide including relapse rates after weaning or discontinuing budesonide. Clinical response was observed in 57% (8/14) of those taking budesonide compared to 21% (3/14) of those in the placebo arm. Complete histologic response (significant reduction of the infiltrate in the lamina propria) was observed in 9/14 in the budesonide group, with 4/14 reaching partial response compared to only 4/14 achieving partial response and 8 others achieving no response in the placebo group.</P>
<P>
<LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK> conducted a randomized, double blind, placebo-controlled trial of budesonide (tapering doses over 8 weeks; 9 mg/day for 4 weeks, 6 mg/day for 2 weeks and 3 mg/day for 2 weeks plus 8 week treatment-free follow-up) versus matched placebo to determine the effect on clinical response in patients (n = 20, 16 females) aged &gt; 18 years with clinically and histologically confirmed active collagenous colitis (clinical: &gt; 4 stools/day and/or stool weight &gt; 200 g/day averaged over 3 days pre-treatment; negative stool samples for pathogens, parasites, and ova; histological: collagen layer &gt; 7 um; inflammation was graded on a scale (0 to 3) independently by 2 pathologists). Pateints were excluded from study if they had other chronic gastrointestinal diseases; clinically significant renal or hepatic disease; been treated with anti-inflammatory drugs (aminosalicylates, corticosteroids, azathioprine) in the previous 3 months; or were pregnant or breast feeding. Outcomes evaluated were clinical response (reduction of stool frequency and/or stool weight by &gt; 50%) and histological response (decrease in inflammation grade or reduction in thickness of the collagen layer). All 10 patients randomized to budesonide achieved a clinical response compared to only 2 in the placebo arm, The budesonide group also had a significant reduction in inflammation compared to the control group.</P>
<P>
<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK> completed a randomized, double-blind, placebo-controlled, multi-centre study in Denmark to evaluate the ability of budesonide to induce and maintain remission in patients aged &gt; 18 years with clinically and histologically confirmed active collagenous colitis plus negative fecal cultures for intestinal pathogens. Clinically active collagenous colitis was defined as &gt; 3 stools/day over 3 days registration and histologically active was subepithelial collagen layer with a thickness &gt; 10 um, inflammation of the lamina propria, and a lymphocytic infiltrate of the epithelium. Patients were excluded if they had been treated with salazopyrine, 5-aminosalicylic acid, budesonide or a systemic glucocorticoid within 3 months of trial enrolment or treated with ketoconazole during the 7 days before random selection. Other exclusionary criteria were other chronic gastrointestinal diseases (including celiac disease), clinically relevant impairment of kidney or liver function, previous intestinal resection or stoma. Fourty-two patients were treated with 9 mg/day budesonide for 6 weeks in an open-label induction phase and the 34 patients who achieved remission were then randomized to 6 mg/day budesonide or matched placebo for 24 weeks. Those still in remission after 24 weeks were followed for an additional 24 weeks after treatment was ceased. If patients relapsed during maintenance or follow-up, they were offered treatment with open-label budesonide (9 mg/day for 6 weeks, followed by budesonide 6 mg/day for 24 weeks). The primary outcome was the proportion of patients maintaining remission after 24 weeks of therapy (budesonide 6 mg/day or matched placebo). Clinical remission was defined as mean stool frequency of &lt; 3 per day. Other outcome measures included: fecal weight (g/day), safety data, maintained histological response (collagen layer &lt;10 um and inflammation score &lt;1), the time to relapse and the rate of relapse after stopping treatment. After 24 weeks of maintenance therapy, 13/17 patients (76.5%) and 2/17 patients (12%) in the budesonide and placebo arms, respectively, were still clinical in remission. Twenty-one patients underwent repeat colonoscopy/sigmoidoscopy with biopsy (n = 10 in budesonide and n = 11 in placebo), the budesonide group demonstrated significant histological improvement, which was not observed in the placebo arm.</P>
<P>
<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK> used an open-label, randomized trial to evaluate the efficacy of mesalazine (800 mg by mouth three times daily) or mesalazine (800 mg by mouth three times daily) + cholestyramine (4 g by mouth once daily) at inducing clinical response over a treatment period of six months in patients with microscopic (lymphocytic or collagenous) colitis. Of the 819 patients that presented to clinic and received a colonoscopy because of chronic watery diarrhoea, 64 were diagnosed with microscopic colitis (23 with collagenous colitis and 41 with lymphocytic colitis), and were then enrolled in the study. Diagnostic criteria included the presence of chronic or recurrent non-bloody diarrhea (clinical) and increased chronic inflammatory infiltrate (plasma cells, lymphocytes, eosinophils) in the lamina propria; increased number of intraepithelial lymphocytes, damage to surface epithelium, with flattening of epithelial cells and/or epithelial loss and detachment and minimal crypt architecture distortion; specific to the diagnosis of collagenous colitis was a subepithelial collagen band &gt;10 um thick, which entraps superficial capillaries, with an irregular lacy appearance at the lower edge of the basement membrane (histological). Patients were excluded if there was a clear correlation between symptoms and consumption of drugs (e.g. NSAIDS, ticlopidine, PPI). The primary outcomes were clinical (complete response was complete resolution of diarrhoea or partial response was improvement without resolution of diarrhoea) and histological (normalization of histologic pattern) response at 6 months. Secondary outcomes included: adverse events; and days to remission or relapse, as well as various lab data (routine blood biochemistry and hematological counts, C-reactive protein, antinuclear antibodies blood assay, serum T4 and thyroid stimulating hormone; IgA-IgG antigliadin, antiendomysium, IgG anti tTG antibody blood assays; and parasitic-bacterial, fecal-stool, and hemo-occult test. A 24-month follow-up with coloscopies and biopsies, annually was also performed. In patients relapsed during follow-up, they were offered a second round of 6 month-therapy. Relapse was defined as stool frequency of &gt;3 soft or liquid stools per day. At 6 months, 20 (91.3%) patients with CC (12 in the mesalazine + cholestyramine arm and eight mesalazine, P&lt;0.01) were in remission.</P>
<P>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> conducted a randomized, double-blind, placebo controlled trial of bismuth salicylate for the treatment of microscopic colitis over an eight week study. Fourteen patients (11 females, aged 35 to 78 years; 9 with thickened subepithelial collagen, 5 without) were randomized, half and half, to receive bismuth subsalicylate (nine 262 mg chewable tablets/ per day in 3 divided doses) versus placebo (identically coloured and flavoured sucrose tablets). Outcomes were based on clinical and histological comparisons; "48 hour fecal weight and consistency, and distal colonic histology (from 16 biopsies obtained by flexible sigmoidoscopy)" were assessed pre and post therapy; patients also kept a journal of stool frequency and consistency. The patients in the placebo group were crossed over to active treatment while blinding was maintained at the end of 8 weeks for an 8 week course of bismuth salicylate. All 7 patients receiving bismuth salicylate achieved decreased stool weight/frequency and improved consistency over the 8 weeks; however changes in the placebo group were "absent or marginal". Once crossed over to active therapy, the placebo group experienced the same improvements.</P>
<P>
<LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK> completed a randomized, placebo-controlled, double-blind study at multiple German centres to evaluate the clinical response of <I>Boswellia serrata</I> extract on patients with collagenous colitis compared to placebo over 6 weeks. Thirty-one patients (aged 18 to 80 years) with clinically and histologically confirmed collagenous colitis ("at least five liquid or soft stools per day on average per week, and a complete colonoscopy performed within the last 4 weeks before randomization") were randomized to receive <I>Boswellia serrata</I> extract (three 400 mg/day; n = 16) or identically matched placebo (n = 15). Patients were excluded in they had received budesonide, salicylates, steroids, prokinetics, antibiotics, ketoconazole, or non-steroidal anti-inflammatory drugs within four weeks of randomization or if they had other endoscopically or histologically verified causes for diarrhea, infectious diarrhea, previous colonic surgery, or known intolerance to <I>Boswellia serrata</I> extract or were pregnant or lactating. The primary endpoint was clinical remission after 6 weeks (stool frequency of &lt; 3 per day); secondary outcomes included histological improvements and quality of life measures. "Patients who did not respond to treatment after 6 weeks were individually unblinded. If they were in the active treatment group, they were judged as treatment failure. If they were in the placebo group, crossover therapy with open-labelled BSE 400 mg, given orally three times daily was offered." Intention to treat analysis demonstrated no significant effect of <I>Boswellia serrata</I> extract compared to placebo on achieving clinical remission, 43.8% vs 26.7%, respectively, P =0.25). Compliance and safety data were also collected.</P>
<P>
<LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> performed a randomized, double-blind, placebo-controlled study was conducted between April 1999 and December 2000 at 35 centres to evaluate the efficacy of oral budesonide (9 mg/day) at inducing clinical remission and improving histology of patients with clinically and histologically active, confirmed collagenous colitis ("at least five liquid or soft stools per day on average per week, and a complete colonoscopy performed within the last 4 weeks before randomization"). Patients were excluded if they had evidence of infectious diarrhea (from culture or biopsy), any other endoscopic or histologic findings (polyps 2 cm, tumors, Crohn&#8217;s disease, ulcerative colitis, ischemic colitis) which may have caused diarrhea, known intolerance to budesonide, pregnancy, lactation, or prior partial colonic resection, or if they had received treatment with budesonide, salicylates, steroids, prokinetics, antibiotics, ketoconazole, or non-steroidal anti-inflammatory drugs within 4 weeks before randomization. Fifty-one patients meeting the inclusion criteria were randomized to budesonide (n = 26) or identically matched placebo (n = 25) for 6 weeks. Outcomes were proportion of patients achieving clinical remission or histological improvement after 6 weeks, with clinical remission defined as average of &lt; 3 soft stools per day during the last week of treatment and histologically defined as change of 2 of 3 of the following parameters: collagen band thickness no more than 10 um or reduced to 50% compared to baseline; improvement of inflammation of the lamina propria; improvement of degeneration of surface epithelium. Patients who did not respond to treatment after 6 weeks were unblinded. If they were in the active treatment group, they were judged as treatment failure. If they were in the placebo group, crossover therapy with open-label budesonide, 9 mg/day po for another 6 weeks. The study reported that 20/26 (76.9%) and 3/25 (12%) patients achieved clinical remission after 6 weeks in the budesonide and placebo groups, respectively. Histological improvement was observed in 14/25 in the budesonide arm compared to only 1/25 in the placebo arm. Sixteen patients who failed the placebo arm entered the cross-over study, 13 achieved clinical remission on open-label budesonide.</P>
<P>The <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK> study was a randomized, double-blind, placebo-controlled trial conducted between April 2004 and March 2007 at 38 centres to evaluate the efficacy of budesonide at inducing remission (9 mg/day for 6 weeks) and maintaining remission (6 mg/day for 6 months) in patients aged &gt;18 years with symptomatic (clinically) and histologically (subepithelial collagen band &gt; 10 um; inflammatory infiltrate in the lamina propria) proven active collagenous colitis. Clinically active defined as "&gt;3 watery/loose stools per day on &#8805; 4 of the previous 7 days and had a history of diarrhoea for &#8805; 4 weeks." Patients were excluded if they had infectious causes for diarrhoea; other inflammatory bowel diseases; history of colonic surgery; celiac disease; malignancies; severe concomitant (organ) diseases that would interfere with the study; at time of inclusion, were being treated 5-aminosalicylates, salicylates (except in doses &#8804;165 mg for cardiovascular prophylaxis), systemic steroids, antibiotics, or NSAIDs (including selective cyclo-oxygenase-2 inhibitors); used of budesonide within the 2 weeks prior to enrolment; known intolerance to budesonide; drug and/or alcohol abuse or were pregnant or lactating. The induction phase had 48 patients who all received 9 mg/day po qd budesonide for 6 weeks; those in remission after 6 weeks were randomized to 6 mg/day po qd budesonide (n = 23) or identically matched placebo (n = 23) for 6 months. Primary endpoint was cumulative rate of relapse at the end of 6 months (maintenance phase); remission had been induced during the 6 week induction phase. Relapse was defined as &gt; 3 stools per day on &#8805; 4 consecutive days. Relapse rates were determined from daily patient diaries. Secondary outcomes were time to relapse during maintenance therapy; the proportions of patients with clinical remission after 6 weeks&#8217; induction therapy and after 2 and 4 months of maintenance therapy; HRQOL outcomes; and changes in histologic variables after 6 months&#8217; maintenance therapy ("thickness of the collagen band (&gt;10 or &lt;10 µm); inflammation of the lamina propria (infiltration with lymphocytes and plasma cells; absent, mild, moderate, or severe); and degeneration of the surface epithelium (absent, or present)"). Histologic improvement defined as improvement in &#8805; 2 variables versus baseline. Safety and tolerability assessments were also performed. At the end of 6 months of maintenance therapy, the cumulative rate of relapse for budesonide maintenance therapy versus placebo was (6/23 [26%] and 15/23 [65%], respectively; P= 0.022.</P>
<P>
<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> conducted an 8 week randomized, double-blind, double-dummy, placebo-controlled, comparative phase-3 trial at 31 hospitals and private clinics in various European countries.The study was to compare the efficacy of budesonide (9 mg/day, n = 30) versus mesalamine (3 g/day, n = 25) versus placebo (n = 37) at inducing clinical and histological remission in patients (n = 92; aged 18-80) with active collagenous colitis (&gt;4 watery or soft stools on &#8805;4 days and &gt;3 stools/day in the week prior to baseline; patients must have also had chronic diarrhoea for &#8805;3 months prior to baseline and have had a colonoscopy within 4 months of baseline; confirmed collagenous colitis with subepithelial collagenous band &gt; 10 um and degeneration of the surface epithelium). Patients were then followed for a 16 week treatment-free phase to determine maintenance of clinical response. Exclusion criteria included: "other significant colonic diseases (i.e. polyps &gt;2 cm, tumors, Crohn&#8217;s disease, ulcerative colitis, ischemic colitis), partial colonic resection, infectious diarrhea, celiac disease (blood tests and/or duodenal histology required), diarrhea caused by other organic diseases of the gastrointestinal tract, treatment with budesonide, <I>Boswellia serrata</I> extract, salicylates, steroids, antibiotics, cholestyramine, nonsteroidal anti-inflammatory, or other immunosuppressant drugs within the last 4 weeks before baseline, malignant disease, severe comorbidity, abnormal hepatic function or liver cirrhosis, renal insufficiency, active peptic ulcer disease, known intolerance or resistance to study drugs, pregnancy, or breast-feeding." All medications take for 8 weeks if responsive. If unresponsive after 4 weeks, or relapsed in the 16 week treatment-free follow-up, patient's removed from study arm and received 9 mg/day of budesonide for the remaining 4 weeks. Primary and secondary outcomes were evaluated at each interim visit (remission phase: 2, 4, 6, 8 weeks; follow-up phase: 8 and 16 weeks). Primary outcomes were: clinical remission defined as &#8804;3 stools/day in the week before the visit and/or histological remission defined as "collagen band thickness 10 mm and no inflammation of the lamina propria with neutrophilic and eosinophilic granulocytes." Secondary outcomes were clinical remission according to the Hjortswang-Criteria of disease activity (mean &lt;3 stools per day, with &lt;1 watery stool per day), "time to remission, number of watery and solid stools per week, abdominal pain, histopathology, tolerability and safety, symptom relapse during treatment-free follow-up, and response to open-label budesonide." Overall budesonide demonstrated the highest efficacy at achieving clinical remission (80%) compared to 44% of those taking mesalamine and 59.5% of those receiving placebo.</P>
<P>
<LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> a multi centre, prospective, randomized, placebo-controlled trial was conducted to examine low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis. Patients (n = 110) &gt;18 years were eligible if they had: a histologically diagnosed for collagenous colitis, watery diarrhoea for &gt;2 weeks in newly diagnosed collagenous colitis or a prescreening history of clinical relapse for &gt;1 week in patients with previously established collagenous colitis and a mean of &#8805;3, including a mean of &#8805;1 watery stool/day, during the week prior to baseline.</P>
<P>The study started with an initial open-label induction phase with budesonide therapy for 8 weeks to achieve clinical remission of collagenous colitis. During the open-label induction phase, all patients received a daily budesonide at a dose of 9mg/day for 4 weeks, then 6 mg/day for 2 weeks, followed by alternate doses of 6mg/day and 3 mg/day for the final 2 weeks. The patients who achieved clinical remission during the last week of the open-label phase were eligible for randomization into a double blind, randomized, placebo-controlled 12 month phase for maintenance of clinical remission. The patients who achieved clinical remission (92/110) were randomized into the budesonide treatment group (n = 44) continued to receive budesonide of 6mg/day and 3 mg/day on alternate days. The patients randomized to the placebo group received two placebo capsules and one placebo capsule on alternate days, administered once a day. Patients in clinical remission at the end of the double blind phase were followed for a 6 month untreated follow-up phase. Clinical remission at 1 year was achieved by 27/44 (61.4%) patients in the budesonide treatment group compared to 8/48 (16.7%) of patients in the placebo group.</P>
<P>
<LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>, a multi-centre, randomized, double-blind, placebo-controlled trial was conducted to examine the ability of prednisolone to induce remission in patients with severe, disabling diarrhoea due to collagenous colitis after a short duration of treatment. Selected patients (n = 12, 11 with collagenous colitis and 1 with lymphocytic colitis) were aged &gt;18 years reporting at least 3 months with diarrhoea without blood or pus and with a stool volume &#8805;350 g/day or &#8805;200 g/day and a stool frequency &#8805;5/day and a histological diagnosis of microscopic colitis. Female patients also needed to use appropriate contraceptive techniques. Patients were diagnosed histologically using a macroscopic normal colonoscopy or sigmoidoscopy plus a normal barium enema and confirmed by an independent pathologist with either lymphocytic colitis or collagenous colitis using the following criteria: &#8220;chronic inflammatory infiltrate in the lamina propria and either a lymphocytic infiltration of at least 20% of epithelial crypt cells (lymphocytic colitis) and/or a subepithelial collagen bond &gt;10 µm in a well-oriented biopsy (collagenous colitis).&#8221; Excluded patients: tested positive for pathogenic bacteria or parasites; failed a normal lactose absorption test and vitamin B12 absorption test, or a normal barium follow through; had celiac disease (confirmed with IgG and IgA antigliadin antibodies and antiendomysium antibodies and/or abnormal histology in duodenal biopsies); had bile acid malabsorption and/or no response to cholestyramine, and/or steatorrhoea; had other gastrointestinal diseases or previous gastrointestinal surgery (exception: cholecystectomy); had other serious diseases, abnormal laboratory tests (haematology, renal function, liver enzymes, urinalysis); had been treated with immunosuppressives within 3 months of randomization; or used medicines with known effects on gastrointestinal functioning including anti-ulcer medication, antacids, antibiotics and NSAIDs. Patients were randomized to prednisolone (n = 9) 50 mg/day po qd for 2 weeks, tapered to 37.5 mg in the 3rd week, or identical placebo tablets (n = 3) for 2 weeks All patients received 12.5 mmol calcium (500 mg)/5 µg vitamin D tablets, twice daily and were not allowed antidiarrhoeal medication. Outcomes were clinical response (remission or effect) after 2 weeks; clinical remission was defined as stool weight &#8804; 200 g/day or frequency &#8804; 2/day; effect was defined as &gt;50% reduction of either stool frequency or weight. Adverse events were also monitored. Remission and effect were attained by 2/9 and 5/9 respectively in the prednisolone arm and 0/3 in both outcomes in placebo.</P>
<P>
<LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK> conducted a randomized, double-blind, placebo-controlled trial at 4 centres to evaluate the ability of AB-Cap-10 (a mixture of L. acidophilus strain LA-5 and B animalis subsp. lactis strain BB-12), a probiotic, to induce clinical response in patients with collagenous colitis over 12 weeks followed by a 5 week follow up. Patients (n = 36) selected were aged &#8805;18 years with confirmed histological diagnosis of collagenous colitis ("a subepithelial collagen band &gt; 10 um in a well oriented section of the mucosa and inflammation of the lamina propria with infiltration of predominantly lymphocytes and plasma cells") that is active (&gt; 21 liquid or soft stools per week or stool weight of &gt; 200 g/day) and untreated for at least 4 weeks prior to study inclusion. Exclusion criteria included: those who were pregnant or breast feeding; had chronic liver or kidney disease, severe vascular or cardiopulmonary disease, malignancy, immunosuppressive disease or treatment, known inflammatory bowel disease besides collagenous colitis (including celiac disease), evidence of infectious diarrhea, prior gastrointestinal surgery other than appendectomy; or had malabsorption syndromes; or those who were had received treatment with aminosalicylates, antibiotics, cholestyramine, nonsteroidal anti-inflammatory drugs, and steroids was not allowed 4 weeks prior to study entrance. Patients were randomized in a 2:1 fashion to receive probiotic AB-Cap-10, n = 21 (containing 0.5 x 10^10 colony-forming units of each bacterium, leading to a total delivery of 1 x 10^10 CFU per capsule) and identically matched placebo, n = 8 for 12 weeks with a 5 week follow up. Patients were assessed at weeks -1, 0, 4, 6, 12, and 16. "The primary end point was the proportion of patients achieving a reduction in the number of stools per week of at least 50% at week 12 in each treatment arm. Secondary end points were changes in bowel frequency, stool consistency, stool weight, abdominal pain and bloating, histopathology of biopsies from the sigmoid colon, scores in the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), use of antidiarrhoeal medication, and registration of side effects of the probiotic." At week 12 the number of patients achieving at least a 50% reduction in the number of stools per week in the probiotic group was 6/21 (29%) compared to 1/8 (13%) in the placebo group.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-11-08 12:47:19 -0500" MODIFIED_BY="John K MacDonald">
<P>This risk of bias for the included studies is summarized in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. The studies included were generally at low risk of bias. Seven studies described the method for used for random sequence generation (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>) and thus were rated at low risk of bias for that item . The remaining studies reported that the patients were randomized, but did not describe the method, which resulted in a rating of unclear risk of bias. Six studies reported adequate methods for allocation concealment ( <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>), which were rated at low risk of bias; the remainder were unclear risk, with no description provided. Adequate methods for blinding were described in the ten of the studies and these studies were rated as low risk of bias (<LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>; <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>). One study did not describe methods used for blinding but reported the study was double-blind and was rated unclear (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>). One study was open label and was rated at high risk of bias for blinding (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>). Eleven trials were at low risk of bias for incomplete outcome data (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>; <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>). <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK> did not report on how many participants completed the study and did not describe any dropouts or withdrawals resulting in a rating of unclear for incomplete outcome data<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK> did not describe any pre-specified outcomes in the manuscript and was rated an unclear risk of bias for selective reportingAll included studies were rated at a low risk for other bias (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>; <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>; <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-11-08 12:49:05 -0500" MODIFIED_BY="John K MacDonald">
<SUBSECTION>
<HEADING LEVEL="3">Induction of response</HEADING>
<P>
<B>Bismuth subsalicylate versus placebo</B>
</P>
<P>
<I>
<U>Clinical response</U>
</I>
</P>
<P>In <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>, 100% (4/4) of patients treated with bismuth subsalicylate achieved a clinical response after 8 weeks, compared to 0% (0/5) of patients treated with placebo (RR 10.80, 95% CI 0.75 to 155.93). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (sequence generation and allocation concealment) and very serious imprecision (4 events; See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). </P>
<P>
<I>Histological response</I>
</P>
<P>In <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>, 100% (4/4) of patients treated with bismuth subsalicylate achieved a histological response after 8 weeks, compared to 0% (0/5) of patients treated with placebo (RR 10.80, 95% CI 0.75 to 155.93). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (sequence generation and allocation concealment) and very serious imprecision (4 events; See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). </P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>Quality of life was not reported as an outcome measure in <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>.</P>
<P>
<I>Adverse events</I>
</P>
<P>No adverse events were reported in either the bismuth subsalicylate or the placebo groups in <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>.</P>
<P>
<I>
<B>Boswellia serrata</B>
</I>
<B> extract versus placebo</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>, 44% (7/16) of patients treated with <I>Boswellia serrata</I> extract achieved a clinical response after 6 weeks compared to 27% (4/15) of patients treated with placebo (RR 1.64, 95% CI 0.60 to 4.49). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (11 events; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). </P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>, there was a slight reduction in the thickness of the subepithelial collagen band and inflammation score in both the <I>Boswellia serrata</I> and placebo groups at the end of 6 weeks of therapy, but no difference compared to baseline or between the groups.</P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>
<LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK> used the "SF-36" survey, a validated 36 item questionnaire measuring both physical and mental components of quality of life at baseline and at the end of 6 weeks of therapy. The mean scores in patients with collagenous colitis were lower at baseline than normal controls. At the end of 6 weeks of therapy, there were no significant changes in quality of life scores in either the <I>Boswellia serrata</I> or placebo groups compared to baseline or between groups.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>In <LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK>, 12.5% (2/16) of patients treated with <I>Boswellia serrata</I> extract reported an adverse event. Of these, 1 patient withdrew from the trial due to hypoglycemia, dizziness and anorexia. The other developed bacterial enteritis but completed the trial. One of 15 patients (7%) in the placebo group reported an adverse event (eczema and Coxsackie virus infection), but completed the trial. There was no significant different between the groups in adverse events or withdrawals due to adverse events. Twelve per cent (2/16) of patients treated with <I>Boswellia serrata</I> extract had an adverse event compared to 7% (1/15) of patients treated with placebo (RR 1.88, 95% CI 0.19 to 18.60). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (3 events; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Six (1/16) of patients treated with <I>Boswellia serrata</I> extract withdrew due to an adverse event compared to 0% (0/15) of patients treated with placebo (RR 2.82, 95% CI 0.12 to 64.39). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (1 event; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). None of the adverse events were considered serious.</P>
<P>
<B>Budesonide versus mesalamine</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>, 80% (24/30) of patients randomized to receive budesonide and 44% (11/25) of patients randomized to receive mesalamine achieved a clinical response (RR 1.82, 95% CI 1.13 to 2.93). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (35 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>, 87% (26/30) and 45% (11/25) of patients randomized to budesonide and mesalamine, respectively, achieved a histological response (RR 1.97, 95% CI 1.24 to 3.13). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (37 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>
<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> reported adverse event data. Forty-seven per cent (14/30) of patients on budesonide and 68% (17/25) of patients on mesalamine experienced at least one adverse event (RR 0.69, 95% CI 0.43 to 1.10). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (31 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Common adverse events reported in this study included headache, nasopharyngitis and dyspepsia. Zero per cent (0/30) of the patients taking budesonide and (4/25) of patients taking mesalamine withdrew due to adverse events (RR 0.09, 95% CI 0.01 to 1.65). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (4 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Zero per cent (0/30) of patients receiving budesonide experienced a serious adverse event, but 12% (3/25) of patients on mesalamine did (RR 0.12, 95% CI 0.01 to 2.21). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (3 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). </P>
<P>
<B>Mesalamine versus placebo</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In
 

<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>, 44% (11/25) of patients administered mesalamine and 60% (22/37) of patients administered placebo had a clinical response (RR 0.74, 95% CI 0.44 to 1.24). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (33 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). </P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>, 45% (11/25) of patients given mesalamine and 50% (19/37) of patients given placebo had a histological response (RR 0.86, 95% CI 0.50 to 1.47). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (30 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). </P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>
<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> provided adverse event data. Sixty eight per cent (17/25) and 54% (20/37) of patients given mesalamine and placebo, respectively, experienced at least one adverse event (RR 1.26, 95% CI 0.84 to 1.88). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (37 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). Sixteen per cent (4/25) and 3% (1/37) of patients from the mesalamine and placebo groups, respectively, withdrew due to an adverse event (RR 5.92, 95% CI 0.70 to 49.90). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (5 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). Twelve per cent (3/25) of patients receiving mesalamine experienced a serious adverse event, while 3% (1/37) of patients receiving placebo experienced such an event (RR 4.44, 95% CI 0.49 to 40.29). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very serious imprecision (4 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). </P>
<P>
<B>Mesalamine versus mesalamine + cholestyramine</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, 73% (8/11) of patients treated with mesalamine alone achieved a clinical response after 6 months compared to 100% (12/12) of patients treated with mesalamine + cholestyramine (RR 0.74, 95% CI 0.50 to 1.08). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to high risk of bias (blinding) and very serious imprecision (20 events; See <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). </P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, 90% (18/20) of patients in the combined mesalamine and mesalamine + cholestyramine groups who underwent a follow up colonoscopy at 6 months had a histological response. It was not clear from the paper in which groups these patients were enrolled and attempts to obtain this information from the authors were unsuccessful.</P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>Quality of life was not reported as an outcome measure in <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, the adverse events that were reported were in the mesalamine + cholestyramine groups; nausea was experienced by two participants (RR 0.22 95% CI 0.01 to 4.07). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to high risk of bias (blinding) and very serious imprecision (20 events; See <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). </P>
<P>
<B>Prednisolone versus placebo</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>, 63% (5/8) of patients treated with prednisolone achieved a clinical response after 2 weeks of therapy, compared to 0% (0/3) of patients treated with placebo (RR 4.89, 95% CI 0.35 to 68.83). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (random sequence generation and allocation concealment) and very serious imprecision (5 events; See <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>). </P>
<P>
<I>Histological response</I>
</P>
<P>In <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>, no patients underwent follow-up colonoscopy or sigmoidoscopy to determine histological response to therapy.</P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>Quality of life was not reported as an outcome measure in <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>In <LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK>, typical corticosteroid-related side effects were common in the prednisolone group, but none were severe enough to cause patient withdrawal from the study. Reported adverse events included abdominal pain, headache, sleep disturbance, mood change, and weight gain.</P>
<P>
<B>Probiotics versus placebo</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>In <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>, 29% (6/21) of patients treated with probiotics achieved a clinical response after 12 weeks compared to 13% (1/8) of patients treated with placebo (RR 2.29, 95% CI 0.32 to 16.13). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (allocation concealment) and very serious imprecision (7 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>).</P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>, no differences in changes of the histopathological features (thickness of the collagen band, inflammation of the lamina propria, detachment of the surface epithelium) between or within groups were observed after 12 weeks of treatment.</P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>
<LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK> used the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), a validated 10-item questionnaire measuring health related quality of life to measure quality of life at baseline and after 12 weeks of treatment with probiotics or placebo. Scores on the SIBDQ range from 10 to 70 with higher scores corresponding with better quality of life. The median baseline SIBDQ score was 46 in the probiotics group compared to 53.5 in the placebo group. After 12 weeks of treatment the median score was unchanged in the placebo group (53.5 to 59.5) but increased significantly in the probiotics group (46 to 55; P &lt; 0.05). After correction for multiple comparisons this difference was no longer statistically significant.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>In <LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK>, a variety of mild adverse events were reported by patients in both the probiotic and placebo groups. Gastrointestinal symptoms, including mild worsening of diarrhea (n = 1), abdominal pain and constipation (n = 2), stomach burn (n = 1), nausea (n = 1), and flatulence (n = 1), were considered possibly related to the probiotic treatment. Twenty-nine per cent (6/21) of participants in the placebo group had an adverse event compared to 50% (4/8) of placebo participants (RR 0.57 95% CI 0.22 to 1.50). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (allocation concealment) and very serious imprecision (10 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). No patients withdrew from the study due to adverse events.</P>
<P>
<B>Budesonide versus placebo</B>
</P>
<P>
<U>
<I>Clinical response</I>
</U>
</P>
<P>A total of 161 patients were enrolled in the four trials (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>, <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>). After 6 to 8 weeks of treatment, pooled analysis revealed 81% (62/77) of patients treated with budesonide achieved a clinical response compared to 36% (30/84) patients treated with placebo (RR 2.98, 95% CI 1.14 to 7.75; random-effects). This analysis was statistically significant for heterogeneity (P=0.001, I<SUP>2</SUP>=81%). Visual inspection of the forest plots revealed an outlier. Sensitivity analysis to exclude <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> from pooled analysis is justified as this study resulted in an abnormally large response rate in the placebo group of 59.5% compared to an average of 19% (12 to 25%) in the other three trials; whereas study method and patient characteristics were comparable within the characteristics described. After exclusion of <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>, the I<SUP>2</SUP> statistic decreased to 0%. Eighty-one per cent (38/47) of budesonide participants achieved clinical response compared to 17% (8/47) of placebo participants (RR 4.56, 95% CI 2.43 to 8.55). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to unclear risk of bias (random sequence generation and blinding in one study and random sequence generation and incomplete outcome data in another study) and serious imprecision (46 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). The number needed to treat to achieve a clinical response to budesonide was 2 patients. </P>
<P>
<U>
<I>Histological response</I>
</U>
</P>
<P>The definition of histological response and criteria used to evaluate such response were comparable across the four trials (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>), although there is consideration for subjective error between the pathologists readings. A quoted description of the criteria and definitions used for the studies are as follows, along with diagnostic criteria described by <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>:</P>
<P>
<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>:</P>
<P>&#8220;Diagnosis involved: subepithelial collagen band on a well-oriented section of the mucosa had the typical feathery appearance of the inferior border and exceeded 10 mm. In addition, an increased mixed inflammatory cell infiltrate in the predominantly mononuclear lamina propria should be present. Other findings may include regenerative epithelial changes with mucin depletion, surface epithelial damage and sloughing, rare infiltration of neutrophils and eosinophils both in the epithelium and the lamina propria.&#8221;</P>
<P>Histologic analysis consisted of the evaluation of the thickness of the collagen band (measured as the mean thickness on the well-oriented section), the degree of infiltration in the lamina propria, and the number of intraepithelial lymphocytes. The infiltrate of the lamina propria was scored semi-quantitatively as normal, slightly increased, or dense.</P>
<P>
<LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>
</P>
<P>Histologic analysis: &#8220;One pathologist measured the thickness of the collagen layer.The other pathologist measured the grade of inflammation in the lamina propria semi-quantitatively on a scale from 0 to 3: 0=no inflammation; 1=mild&#8212;that is, inflammatory infiltrate confined to the upper part of the lamina propria; 2=moderate&#8212;that is, inflammatory infiltrate extending beyond the base of the crypts; and 3=severe&#8212;that is, heavy inflammatory infiltrate occupying the lamina propria and infiltrating the lamina muscularis mucosa.&#8221;</P>
<P>
<LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>
</P>
<P>Histologic analysis: &#8220;On well-oriented sections in which at least 3 adjacent crypts were cut in their vertical plane, the following parameters were evaluated: thickness of the collagen band (µm), inflammation of the lamina propria (semi-quantitative score, 0&#8211;3), and degeneration of the surface epithelium (present or absent). A collagen band thickness of &lt;10 µm post-treatment or a reduction of at least 50% compared with baseline was defined as significant reduction. Significant histologic improvement was defined as improvement of at least 2 of the 3 histologic parameters&#8221;</P>
<P>
<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>
</P>
<P>Histologic analysis: &#8220;On well-oriented sections in which at least 3 adjacent crypts were cut in their vertical plane, we measured the thickness of the collagen band (µm) and inflammation of the lamina propria (semi-quantitative score 0-3). Histologic remission was defined as a collagen band thickness &lt;10 µm and no inflammation of the lamina propria with neutrophilic and eosinophilic granulocytes.&#8221;</P>
<P>A pooled analysis of the four studies, which resulted in total of 161 patients with histological remission occurring in 60/77 (78%) and 27/84 (32%) of patients receiving budesonide and placebo, respectively (RR 2.68 95% CI 1.37 to 5.24), which did demonstrate a statistically significant response. As with the clinical response analysis, histological response was statistically significant for heterogeneity (P=0.04, I<SUP>2</SUP>=63%). The same rational was applied to histological response after visual inspection of the forest plots and <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> was excluded due to unusually high responses in the placebo group (51% compared to the 4 to 30% reported in the other 3 studies). A sensitivity analysis excluding <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> reduced the I<SUP>2</SUP> statistic to heterogeneity to 32% (P = 0.23), which is no longer significant. Seventy-two per cent (34/47) of budesonide participants achieved histological response compared to 17% (8/47) of placebo participants (RR 4.15, 95% CI 2.25 to 7.66). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to unclear risk of bias (random sequence generation and blinding in one study) and serious imprecision (42 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). </P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>
<LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> provided quality of life (reported in Madisch 2005). The validated Gastrointestinal Quality of Life Index (GIQLI) was used to measure quality of life at baseline and after six weeks of treatment with budesonide or placebo. Scores on the GIQLI range from 0 to 144 with higher scores corresponding with better quality of life. A complete quality of life assessment was calculated for 29 trial participants (budesonide: n = 17; placebo: n = 12). At baseline, the mean GIQLI score for the trial participants was low (mean = 76). The mean baseline GIQLI score was 67 in the budesonide group and 86 in the placebo group. After six weeks of treatment the mean GIQLI score remained unchanged in the placebo group (86 to 88) but increased significantly in the budesonide group (67 to 92; P &lt; 0.001). Neither <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK> nor <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK> measured quality of life using a validated instrument.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>Adverse events for budesonide in the induction and maintenance of response is analysed as a pooled analysis below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Maintenance of response</HEADING>
<P>
<B>Budesonide versus placebo</B>
</P>
<P>
<U>
<I>Maintenance of clinical response</I>
</U>
</P>
<P>A pooled analysis of three studies showed that 68% (57/84) of patients receiving budesonide maintained remission at their respective study endpoints, whereas only 20% (18/88) of patients receiving placebo maintained remission (RR 3.30 95% CI 2.13 to 5.09). This analysis was not statistically significant for heterogeneity (P=0.21, I<SUP>2</SUP>=35%). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to unclear risk of bias (random sequence generation and allocation concealment in one study) and serious imprecision (75 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). </P>
<P>
<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK> continued to follow patients for an additional 24 weeks after stopping therapy. At the end of this period, 4 of 17 patients (24%; 95% CI 9% to 48%) initially randomized to budesonide and 2 of 17 patients (12%; 95% CI 2% to 36%) initially randomized to placebo maintained their response (P = 0.38). The median time to relapse after stopping 6 weeks of open-label budesonide treatment was 207 days in the budesonide group compared to 45 days in the placebo group (P &lt; 0.02). The median time to relapse after stopping active treatment (6 + 24 weeks in the budesonide group; 6 weeks in the placebo group) was 40 versus 45 days, respectively (P = NS).</P>
<P>In <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK> the mean time to relapse in the budesonide group was 37 days compared to 53 days in the placebo group (P = NS).</P>
<P>
<LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> had a six month follow-up of the patients maintaining remission at treatment cessation. Within the 6 months, only 18% of those originally in remission had maintained it (after 1 year treatment + 6 month follow up) with a median time to relapse after stopping budesonide of 40 (95% CI 27 to 57) days.</P>
<P>
<U>
<I>Maintenance of histological response</I>
</U>
</P>
<P>In <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK> and <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>, 25 patients assigned to budesonide with a maintained clinical response underwent a follow up colonoscopy or sigmoidoscopy at the end of 6 months of treatment. Of these, 19 patients had also maintained their histological response, representing 48% (19/40) of the initial patient cohort randomized to budesonide. In comparison, 19 patients assigned placebo with a maintained clinical response also underwent a follow up colonoscopy or sigmoidoscopy at the end of 6 months of treatment. Six of these patients, representing 15% (6/40) of the initial patient cohort randomized to placebo, had a maintained histological response. The pooled RR for maintenance of histological response was 3.17 (95% CI 1.44 to 6.95). This was not significant for heterogeneity (P=0.60, I<SUP>2</SUP>=0%). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (random sequence generation and allocation concealment in one study) and very serious imprecision (25 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). </P>
<P>
<U>
<I>Quality of life</I>
</U>
</P>
<P>Quality of life was not reported as an outcome measure in either <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK> or <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>.</P>
<P>
<U>
<I>Adverse events</I>
</U>
</P>
<P>Five out of the seven trials (<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>; <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK>) reported the proportion of patients experiencing at least one adverse event and four studies reported withdrawals due to adverse events (<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>). Four trials (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>), reported serious adverse events. <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK> reported only minor adverse events related to study medications, but did not report them separately for the budesonide and placebo groups. <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK> did not report adverse events as an outcome measure. In <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>, 12 of 42 patients reported a mild adverse event during the 6 week open-label induction period with budesonide. Of these, 1 patient with leg cramps withdrew from the study. In the maintenance phase, 4 of 17 patients treated with budesonide reported mild adverse events. One patient suffered a subarachnoid hemorrhage, not related to the study medication, but leading to study withdrawal. Seven of 17 patients in the placebo group reported mild adverse events. One patient developed depression, not related to the study medication, but leading to study withdrawal. This data was included in the above pooled analysis of adverse events. Adverse events in <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> were more common in patients treated with budesonide (39%) than placebo (12%). Two patients (8%) in the budesonide group (1 with nausea, headache, increase in body weight, and disturbed sleep; the other with upper abdominal discomfort) and 1 patient (4%) in the placebo group (arthralgia) withdrew from the study due to an adverse event. All other events were minor. In <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>, 8 patients in each group reported an adverse event. None were thought to be related to the study medication. Three patients in the budesonide group and 1 in the placebo group withdrew due to adverse events. There were no severe adverse events. <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> provided us with their adverse event data. Forty-seven per cent (14/30) and 54% (20/37) of patients receiving budesonide and placebo, respectively, experienced at least one adverse event. The most common adverse events were headache, nasopharyngitis and dyspepsia. There were no serious adverse events in the budesonide group, but one patient receiving placebo experienced one. No patients receiving budesonide withdrew due to an adverse event, while one patient did so receiving placebo (<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>). <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> reported that adverse drug reactions occurred in 7/44 patients receiving budesonide and 5/48 patients on placebo, but did not describe what type of reaction.</P>
<P>Pooled adverse event data showed no statistically significant difference in adverse event rates between budesonide and placebo. Data were pooled regardless of whether the study was an induction or maintenance trial. Forty-nine per cent (68/140) of patients given budesonide and 42% (63/150) of patients given placebo experienced at least one adverse event (5 studies, 290 patients, RR 1.18, 95% CI 0.92, 1.51). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to unclear risk of bias (random sequence generation and allocation concealment in one study and allocation concealment in another study) and serious imprecision (131 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). Seven per cent (10/140) and 7% (11/150) of patients administered budesonide and placebo, respectively, withdrew due to adverse events (5 studies, 290 patients, RR 0.97, 95% CI 0.43 to 2.17). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (random sequence generation and allocation concealment in one study and allocation concealment in another study) and very serious imprecision (21 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). Serious adverse events were rare, with 1% (1/84) patients receiving budesonide and 1% (1/91) of patients receiving placebo experiencing one (4 studies, 175 patients, RR 1.11, 95% CI 0.15 to 8.01). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (random sequence generation and blinding in one study and random sequence generation and allocation concealment in another study) and very serious imprecision (2 events; See <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>). </P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-11-08 12:50:02 -0500" MODIFIED_BY="John K MacDonald">
<P>In the past, the treatment of collagenous colitis had been mainly based on small case series and uncontrolled trials utilizing a wide variety of therapeutic choices, many of which have been reported to be effective (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). However, collagenous colitis is a disorder with a variable clinical course, characterized by periods of spontaneous improvement or exacerbation of symptoms, and such uncontrolled studies are subject to bias due to "regression towards the mean". Patients enter these studies when their symptoms are at their worst, and the improvement seen with treatment may simply be due to the spontaneous improvement in their disease. As a result, randomized trials, which eliminate this bias, have been performed. Twelve trials (476 participants with collagenous colitis) assessed bismuth subsalicylate, <I>Boswellia serrata</I> extract, budesonide, mesalamine with or without cholestyramine, probiotics, and prednisolone for induction of response and three trials (172 participants) assessed budesonide for maintenance of response in collagenous colitis. All of these studies have relatively small numbers of subjects. However, the high rates of clinical and histological response, particularly for budesonide, are encouraging in assisting to define effective therapies for this disorder. In addition, budesonide is well-tolerated and also appears to improve patients' quality of life. The results for budesonide were consistent across the four randomized trials for induction of response and the three randomized trials for maintenance of response, although the GRADE analysis indicates that the overall quality of the evidence is low due to sparse data and unclear risk of bias in some studies. </P>
<SUBSECTION>
<HEADING LEVEL="3">Induction of response</HEADING>
<P>
<B>Bismuth subsalicylate</B>
</P>
<P>The <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> study of bismuth subsalicylate included only nine patients with collagenous colitis. Although treatment with bismuth subsalicylate was effective in achieving clinical and histological responses in this study (both outcomes 100% versus placebo 0%), it is difficult to make any definite conclusions based on such a small number of individuals. The GRADE analysis was very low quality due to very sparse data and unclear risk of bias which indicates that we are very uncertain about the results. Nonetheless, therapy appears to be safe and well-tolerated in this study and in nonrandomized studies (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). A trial of bismuth subsalicylate, nine 262 mg/day tablets in 3 divided doses for 8 weeks may be reasonable in a patient with collagenous colitis.</P>
<P>
<I>
<B>Boswellia serrata</B>
</I>
<B> extract</B>
</P>
<P>
<LINK REF="STD-Madisch-2007" TYPE="STUDY">Madisch 2007</LINK> included 31 patients with collagenous colitis in the trial of <I>Boswellia serrata</I> extract. Although more patients in the <I>Boswellia serrata</I> extract group than the placebo group achieved a clinical response (44% versus 27%), there may have been a lack of power to show a statistically significant difference given the small numbers of patients in each group. <I>Boswellia serrata</I> extract may have no effect on colonic histology or quality of life, but may be well-tolerated. The GRADE analysis was low quality due to very sparse data which indicates that we are uncertain about the benefits and harms of <I>Boswellia serrata</I> extract. </P>
<P>
<B>Mesalamine +/- cholestyramine</B>
</P>
<P>
<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK> included 23 patients with collagenous colitis in the trial of mesalamine versus mesalamine + cholestyramine. More patients in the combined mesalamine + cholestyramine group than the mesalamine alone group achieved a clinical response (100% versus 73%), but there may have been a lack of power to show a statistically significant difference given the small numbers of patients in each group. A GRADE analysis indicated that the overall quality of the evidence was very low due to very sparse data and high risk of bias in this study. A histological response was achieved in most patients in both groups at the end of treatment. The therapies appear to be well-tolerated. Quality of life was not reported in this study. This trial was unblinded and there was no placebo group. Some of the measured effect in both groups may have been due to spontaneous improvement of the disease. We are uncertain if mesalamine 800 mg/day three times with or without cholestyramine 4 g/day is effective for treating patients with active collagenous colitis.</P>
<P>
<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> examined 92 patients receiving mesalamine alone (n= 25), budesonide alone (n= 30) and placebo (n= 37). Low quality evidence suggests that mesalamine alone may be less effective than budesonide for inducing clinical response in people with collagenous colitis. Low quality evidence suggests that mesalamine may be no more effective than placebo for inducing both clinical and histological response. In fact, the treatment group receiving mesalamine was stopped prematurely due to futility. Overall we are uncertain about the benefits and harms of mesalamine treatment in people with collagenous colitis. </P>
<P>
<B>Prednisolone</B>
</P>
<P>
<LINK REF="STD-Munck-2003" TYPE="STUDY">Munck 2003</LINK> included only 11 patients with collagenous colitis in the trial studying prednisolone. Of these, eight were assigned prednisolone and three were assigned placebo. Although there was a trend towards achieving a clinical response in patients on prednisolone compared to placebo (63% versus 0%), there may have been a lack of power to show a difference given the small numbers of patients in each group. Additionally, the two week course of therapy may have been too short to show a benefit with prednisolone, when compared to the 6 to 8 weeks of treatment used in the budesonide trials. Follow-up colonoscopy was not performed and quality of life was not measured in this study. Typical corticosteroid-related side effects were common in prednisolone-treated patients. A GRADE analysis indicates that the overall quality of the evidence is very low due to very sparse data and unclear risk of bias. Overall we are very uncertain about the benefits and harms of prednisolone 50 mg/day for treating collagenous colitis.</P>
<P>
<B>Probiotics</B>
</P>
<P>
<LINK REF="STD-Wildt-2006" TYPE="STUDY">Wildt 2006</LINK> included 29 patients with collagenous colitis in the trial of probiotics. Probiotics had no statistically significant effect upon clinical (probiotics 29% versus placebo 13%) or histological response. However, there may have been a lack of power to show a difference given the small numbers of patients in each group. Probiotic treatment had no effect on histology or quality of life, but appeared to be well-tolerated. A GRADE analysis indicates that the overall quality of the evidence is very low due to very sparse data and unclear risk of bias. Overall we are very uncertain about the benefits and harms of probiotics for treating people with collagenous colitis.</P>
<P>
<B>Budesonide</B>
</P>
<P>A pooled analysis suggests that budesonide may be effective for the treatment of collagenous colitis, with very high clinical (81% compared to 36% for placebo) and histological (ranging from 61% to 100% for budesonide and 4% to 50% for placebo) response rates (<LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK>; <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>; <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK>; <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>). However, a high degree of heterogeneity was detected for this analysis (I<SUP>2</SUP> = 81%). Sensitivity analysis revealed that <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> was an outlier, which after visual inspection of the forest plots can be explained by the unusually high rate of remission in the placebo group compared to the other trials included for that comparison. After excluding <LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK> the clinical response rate is 17% in the placebo group and 81% in the budesonide group and the I<SUP>2</SUP> value drops to 0%. A GRADE analysis indicates that the overall quality of the evidence for this outcome is low due to sparse data and unclear risk of bias in two studies in the pooled analysis. Low quality evidence also suggests that budesonide may be effective for inducing histological response in people with collagenous colitis. Budesonide may improve patients' quality of life. <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> provides long term follow-up data showing that clinical relapse may occur after cessation of budesonide therapy. However, re-initiation of budesonide therapy may be beneficial for patients who experience clinical relapse. <LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>, <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK> and <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> reported no serious adverse effects. Other uncontrolled studies using budesonide in collagenous colitis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) have reported this therapy as being generally well-tolerated. In addition, trials performed in patients with Crohn's disease (<LINK REF="REF-Greenberg-1994" TYPE="REFERENCE">Greenberg 1994</LINK>, <LINK REF="REF-Greenberg-1996" TYPE="REFERENCE">Greenberg 1996</LINK>) report a similar adverse event profile, with less systemic effects than are observed with conventional corticosteroids. <LINK REF="STD-Miehlke-2002" TYPE="STUDY">Miehlke 2002</LINK> used 3 mg/day of budesonide for 6 weeks, while <LINK REF="STD-Baert-2002" TYPE="STUDY">Baert 2002</LINK> used a single 9 mg/day dose of budesonide for 8 weeks. Two studies used 9 mg/day of budesonide for 4 weeks (<LINK REF="STD-Bonderup-2003" TYPE="STUDY">Bonderup 2003</LINK>) and 8 weeks (<LINK REF="STD-Miehlke-2014" TYPE="STUDY">Miehlke 2014</LINK>), 6 mg/day for 2 weeks and 3 mg/day for 2 weeks. Low quality evidence suggests that budesonide 9 mg/day orally or in a tapering course for 6 to 8 weeks may be an effective and well-tolerated therapy for inducing clinical and histological response and improving quality of life in patients with active collagenous colitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Maintenance of response</HEADING>
<P>
<B>Budesonide</B>
</P>
<P>
<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>, <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK> and <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> included 172 patients who had achieved a clinical response with open-label budesonide in their trials of budesonide maintenance therapy of collagenous colitis. At the end of 6 months, more patients assigned to budesonide than placebo had maintained their clinical response (75% versus 25%). Although not all patients underwent a follow-up colonoscopy or flexible sigmoidoscopy at the end of treatment, more patients assigned to budesonide than placebo had also maintained their histological response (48% versus 15%) (<LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK>; <LINK REF="STD-Miehlke-2008" TYPE="STUDY">Miehlke 2008</LINK>). A GRADE analysis indicates that the overall quality of the evidence for these outcomes is low due to sparse data and unclear risk of bias in two studies in the pooled analysis. <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> showed that after 12 months of study 61% of patients receiving low dose budesonide were still in remission compared to 17% of those in the placebo arm. No serious adverse events due to budesonide occurred, although one patient suffered a sub-arachnoid haemorrhage in that study arm and had to cease treatment. Quality of life was not reported. After the 6 and 12 months of therapy, <LINK REF="STD-Bonderup-2009" TYPE="STUDY">Bonderup 2009</LINK> and <LINK REF="STD-Munch-2016" TYPE="STUDY">Munch 2016</LINK> continued to follow patients in each group for 6 months. Most patients relapsed off treatment. The median time to relapse was not different in the budesonide group compared to the placebo group once the active drug (either open-label budesonide induction therapy or blinded budesonide maintenance therapy) had been stopped. This suggests that the effect of budesonide at maintaining response is not sustained once the drug is discontinued. Overall low quality evidence suggests that budesonide 6 mg/day may be effective at maintaining both clinical and histological response in patients with active collagenous colitis induced by budesonide, and may be well-tolerated.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-11-08 12:50:18 -0500" MODIFIED_BY="John K MacDonald">
<IMPLICATIONS_PRACTICE MODIFIED="2017-11-08 12:50:07 -0500" MODIFIED_BY="John K MacDonald">
<P>Collagenous colitis is a cause of chronic diarrhea. There are numerous case series and anecdotal reports of success with various pharmacological measures for treating collagenous colitis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Randomized trials, which provide stronger evidence for efficacy, have also been performed, assessing both induction and maintenance of response. It should be noted that 'response' does not necessarily imply 'remission', and the definitions of response, both clinically and histologically, vary between trials. There are no standardized criteria for either clinical or histological remission in collagenous colitis. Until such criteria are established, no conclusions can be made about the effectiveness of the therapies assessed in these trials for inducing or maintaining a true remission in patients with collagenous colitis. Low quality evidence suggests that budesonide may be effective for inducing and maintaining clinical and histological responses in patients with collagenous colitis. Budesonide may improve quality of life, and appears to be well-tolerated at least over 6 months of therapy. We are uncertain about the benefits and harms of treatment with bismuth subsalicylate, <I>Boswellia serrata</I> extract, mesalamine with or without cholestramine, prednisolone and probiotics. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-11-08 12:50:18 -0500" MODIFIED_BY="John K MacDonald">
<P>Collagenous colitis is a chronic condition and some patients require long-term therapy to prevent relapses. The utility of budesonide in this setting requires further investigation.</P>
<P>Although budesonide may be safe and effective for treating collagenous colitis, significant cost and theoretical potential for toxicity with long-term use warrant consideration of less-proven interventions. The favourable results in one small trial of bismuth subsalicylate, a safe and inexpensive therapy, justify larger trials with this drug. The trials assessing <I>Boswellia serrata</I> extract and probiotics included small numbers of patients and may have lacked the power necessary to show a difference between active treatment and placebo should one exist. Larger trials of these treatments may be considered. Prednisolone may also warrant further investigation. The trial included here included only a very small number of patients, and may have lacked the power necessary to show a difference between placebo and prednisolone treated patients, should one exist. In addition, the two week course of therapy that was used is relatively short compared to the 6 to 8 weeks of therapy that was used in the bismuth subsalicylate and budesonide studies. It may be that a longer course of treatment than two weeks is necessary to obtain significant clinical improvement. Mesalamine and mesalamine + cholestyramine seem to be effective in treating collagenous colitis. However, neither of these treatments has been assessed in a blinded, placebo-controlled trial, which would provide better evidence for their effectiveness.</P>
<P>The difference between 'response' and 'remission' in collagenous colitis may be important. Since standardized definitions of clinical and histological remission do not exist, the outcome measures defining response vary between trials of treatments of collagenous colitis, and thus the effectiveness of therapies at inducing and maintaining true disease remission are unknown. However, recently <LINK REF="REF-Hjortswang-2009" TYPE="REFERENCE">Hjortswang 2009</LINK> examined how various symptoms related to health-related quality of life scales. Based on their analysis, they proposed that remission in collagenous colitis should be defined as less than three stools per day and less than one watery stool per day on average. This has not been validated yet, but this is an area to be addressed with further research.</P>
<P>Additionally, inclusion criteria defining histological features of collagenous colitis and clinical activity vary between trials, so that patients in different trials may not be comparable. If standardized definitions for clinical and histological features, disease activity and remission for collagenous colitis are established, trials studying therapies could use uniform inclusion criteria and outcome measures, allowing more accurate assessment of treatment effectiveness and comparisons between trials.</P>
<P>Lymphocytic colitis is a related but histologically different disorder from collagenous colitis. Some studies in the literature include both these diseases under the broader title 'microscopic colitis' when reporting therapeutic success. Whether or not therapies for collagenous colitis should be offered to patients with lymphocytic colitis is currently being investigated in randomized controlled trials. Budesonide, in particular, may be a promising therapy for lymphocytic colitis (<LINK REF="REF-Chande-2017" TYPE="REFERENCE">Chande 2017</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-03-13 14:41:06 -0400" MODIFIED_BY="John K MacDonald">
<P>Partial funding for the Cochrane IBD Group (April 1, 2016 - March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-11-08 12:50:28 -0500" MODIFIED_BY="John K MacDonald">
<P>Tahir S Kafil: None known.</P>
<P>Tran M Nguyen: None known.</P>
<P>Petrease H Patton: None known.</P>
<P>John K MacDonald: None known.</P>
<P>Nilesh Chande has received consulting fees from AbbVie, Janssen, Takeda, and Ferring; and speaker's fees from AbbVie, Janssen, and Actavis. All of these financial activities are outside the submitted work. </P>
<P>John WD McDonald: None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF MODIFIED="2017-11-08 12:50:32 -0500" MODIFIED_BY="John K MacDonald">
<P>We updated the methods to include a full risk of bias assessment for the included studies. We utilized the GRADE criteria to assess the overall quality of the evidence supporting the primary and secondary outcomes. A PRISMA diagram was used to document the study flow.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-11-08 19:15:57 +0000" MODIFIED_BY="John MacDonald">
<STUDIES MODIFIED="2017-11-08 12:57:54 -0500" MODIFIED_BY="John K MacDonald">
<INCLUDED_STUDIES MODIFIED="2017-11-08 12:57:54 -0500" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Baert-2002" MODIFIED="2017-05-30 16:01:51 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Baert 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-05-30 13:55:53 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, et al</AU>
<TI>Budesonide in collagenous colitis: A prospective double blind placebo controlled trial with histologic follow-up</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>Suppl III A250</NO>
<PG>966</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:55:53 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035469"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:55:59 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, et al</AU>
<TI>Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:55:59 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 16:01:51 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035468"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonderup-2003" MODIFIED="2017-05-30 15:51:43 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Bonderup 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-30 13:56:05 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Bach-Hansen J, Madsen P, Vestergaard V, Fallingborg J, Teglbjaerg PS</AU>
<TI>Expression of inducible nitric oxide synthase (iNOS) mRNA in colonic mucosa in collagenous colitis - Correlation to the histological and clinical activity and the effect of budesonide treatment</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4 Suppl 2</NO>
<PG>A154-5</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:56:05 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035472"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:56:15 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J</AU>
<TI>Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>2</NO>
<PG>248-51</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:56:15 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035473"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:56:27 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J</AU>
<TI>Budesonide treatment of collagenous colitis: a randomised, double-blind, placebo controlled trial with morphometric analysis</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>2</NO>
<PG>248-51</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:56:27 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035474"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:56:36 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Hansen JB, Madsen P, Vestergaard V, Fallingborg J, Teglbjaerg PS</AU>
<TI>Budesonide treatment and expression of inducible nitric oxide synthase mRNA in colonic mucosa in collagenous colitis</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>10</NO>
<PG>1095-9</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:56:36 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035475"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:51:43 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonderup-2009" MODIFIED="2017-05-30 15:52:58 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Bonderup 2009" YEAR="2008">
<REFERENCE MODIFIED="2017-05-30 13:56:47 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>Bonderup O, Hansen J, Teglbjaerg P, Christensen L, Fallingborg J</AU>
<TI>Long-term budesonide treatment of collagenous colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>2007</YR>
<PG>No. FP-247</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:56:47 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035477"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:52:12 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Bach-Hansen J, Teglbjaerg PS, Christensen LA, Fallingborg J</AU>
<TI>Long-Term Budesonide Treatment of Collagenous Colitis - a Randomized, Double Blind, Placebo Controlled Trial</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<NO>4 Suppl 1</NO>
<PG>A487-8</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:52:12 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035478"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:57:02 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Hansen JB, Teglbjrg PS, Christensen LA, Fallingborg JF</AU>
<TI>Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial</TI>
<SO>Gut</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>1</NO>
<PG>68-72</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:57:02 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035479"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:52:58 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035476"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-2007" MODIFIED="2017-05-30 15:52:18 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Calabrese 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-05-30 15:51:52 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese C, Fabbri A, Areni A, Zahlane D, Scialpi C, Di Febo G</AU>
<TI>Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>6</NO>
<PG>809-14</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:51:52 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035481"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:52:18 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035480"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fine-1999" MODIFIED="2017-05-30 15:52:11 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Fine 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-05-30 15:52:11 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fine K, Ogunji F, Lee E, Lafon G, Tanzi M</AU>
<TI>Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<NO>4</NO>
<PG>A880</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:52:11 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035483"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:52:05 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035482"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madisch-2007" MODIFIED="2017-05-30 15:56:48 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Madisch 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-05-30 15:56:40 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madisch A, Miehlke S, Eichele E, Bethke B, Mrwa J, Wilhelms G, et al</AU>
<TI>Boswellia serrata extract for the treatment of collagenous colitis: a randomized double-blind, placebo-controlled, multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>4 Suppl 2</NO>
<PG>A581</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:56:40 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035485"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:56:07 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, et al</AU>
<TI>Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled multicenter trial</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>12</NO>
<PG>1445-51</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:56:07 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035486"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:56:48 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035484"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke-2002" MODIFIED="2017-05-30 15:56:29 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Miehlke 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-05-30 15:56:29 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madisch A, Heymer P, Voss C, Wigginghaus B, Bastlein E, Bayerdorffer E, et al</AU>
<TI>Oral budesonide therapy improves quality of life in patients with collagenous colitis</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>312-6</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:56:29 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035488"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:52:23 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madisch A, Miehlke S, Heymer P, Bethke B, Baestlein E, Lehn N, et al</AU>
<TI>Oral budesonide therapy improves quality of life in patients with collagenous colitis-results of placebo-controlled, multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>4 Suppl. 1</NO>
<PG>A191</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:52:23 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035489"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:55:14 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Heymer P, Bethke B, Baestlein E, Meier E, Bartram HP, et al</AU>
<TI>Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>4</NO>
<PG>978-84</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:55:14 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035490"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:52:33 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Heymer P, Ochsenkuehn T, Baestlein E, Yarian G, Morgner A, et al</AU>
<TI>Oral budesonide is highly effective in the treatment of collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>125</VL>
<NO>5 Suppl. 1</NO>
<PG>A-40</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:52:33 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035491"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:54:57 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Voss C, Kuhlisch E, Morgner A, Heymer P, et al</AU>
<TI>Long-term follow-up and predictive factors for clinical relapse in patients with collagenous colitis after induction of remission with budesonide capsules</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4 Suppl 2</NO>
<PG>A465</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:54:57 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035492"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:56:18 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Voss C, Morgner A, Heymer P, Kuhlisch E, et al</AU>
<TI>Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>11-12</NO>
<PG>1115-9</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:56:18 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035493"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:55:07 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035487"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke-2008" MODIFIED="2017-11-08 12:57:54 -0500" MODIFIED_BY="John K MacDonald" NAME="Miehlke 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-05-30 13:52:47 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Bethke B, Morgner A, Baretton G, Stolte M</AU>
<TI>Oral budesonide or maintenance treatment of collagenous colitis: a randomised, placebo-controlled, double-blind trial</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<NO>4 Suppl. 1</NO>
<PG>A488-9</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:52:47 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035495"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-08 12:57:54 -0500" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, et al</AU>
<TI>Oral budesonide for maintenance treatment of collagenous colitis: a randomized, placebo controlled, double-blind trial</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>135</VL>
<PG>1510-16</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:54:23 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035496"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:52:59 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, et al</AU>
<TI>Remission-maintaining therapy of collagenous colitis with Budesonide - a randomised, double-blind, placebo-controlled multi-centre study</TI>
<SO>Zeitschrift fur Gastroenterologie</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>9</NO>
<PG>932</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:52:59 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035497"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:54:16 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlish E, Henker C, et al</AU>
<TI>Budesonide for maintenance treatment of collagenous colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>2007</YR>
<PG>No. PS-M-13</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:54:16 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035498"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 16:00:30 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke-2014" MODIFIED="2017-05-30 15:54:00 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Miehlke 2014" YEAR="2012">
<REFERENCE MODIFIED="2017-05-30 13:53:14 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Kupcinskas L, Heptner G, Böhm G, Marks H, et al.</AU>
<TI>Double-blind, double-dummy, randomized, placebo-controlled, multicenter trial of budesonide and mesalamine in collagenous colitis</TI>
<SO>Gastroenterology</SO>
<YR>May 2012</YR>
<VL>142</VL>
<NO>5 (Suppl 1)</NO>
<PG>S211</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:53:09 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035500"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:53:44 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Kupcinskas L, Petrauskas D, Böhm G, Marks H, et al.</AU>
<TI>Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis</TI>
<SO>Gastroenterology</SO>
<YR>2014</YR>
<VL>146</VL>
<NO>4</NO>
<PG>1222-30</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:53:44 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:53:55 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Kupcinskas L, Petrauskas D, Heptner G, Böhm G, et al</AU>
<TI>European multicenter trial of budesonide and mesalazine for short-term treatment of active collagenous colitis (BUC60/COC)</TI>
<SO>Journal of Crohn's and Colitis</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>S214</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:53:55 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035502"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:53:29 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Mohrbacher R.</AU>
<TI>Double-blind, double-dummy, randomized, placebo-controlled, multicenter trial of budesonide and mesalamine in collagenous colitis</TI>
<SO>Email Correspondance</SO>
<YR>July 30, 2012</YR>
<IDENTIFIERS MODIFIED="2017-05-30 13:53:29 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035503"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:54:00 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munch-2016" MODIFIED="2017-05-30 13:55:25 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Munch 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-11-30 21:59:36 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Münch A, Bohr J, Miehlke S, Benoni C, Olesen M, Öst A, et al</AU>
<TI>Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled, 12-month trial</TI>
<SO>Gut</SO>
<YR>2016</YR>
<VL>65</VL>
<PG>47-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035505"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:54:13 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munch A, Bohr J, Miehlke S, Benoni C, Olesen M, Ost A, et al</AU>
<TI>Clinical remission and quality of life in collagenous colitis: a one-year, randomised, placebo-controlled study with low-dose budesonide (BUC-63/ COC)</TI>
<SO>Gastroenterology</SO>
<YR>2014</YR>
<VL>146(5 suppl. 1)</VL>
<PG>S586</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035506"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 13:55:25 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munch A, Bohr J, Miehlke S, Benoni C, Olesen M, Ost A, et al</AU>
<TI>Low-dose budesonide maintains clinical remission and quality of life in collagenous colitis over a one year period: results from the randomised, placebo-controlled BUC-63/COC trial</TI>
<SO>Journal of Crohn's and Colitis</SO>
<YR>2014</YR>
<VL>8</VL>
<PG>S52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035507"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-11-28 13:02:26 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035504"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munck-2003" MODIFIED="2017-05-30 15:53:42 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Munck 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-30 15:53:33 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munck LK, Kjeldsen J, Philipsen E, Fischer Hansen B</AU>
<TI>Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>6</NO>
<PG>606-10</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:53:33 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035509"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:53:42 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035508"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wildt-2006" MODIFIED="2017-05-30 15:53:52 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Wildt 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-05-30 15:53:19 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wildt S, Munck LK, Vinter-Jensen L, Hansen BF, Nordgaard-Lassen I, Christensen S, et al</AU>
<TI>Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis</TI>
<SO>Inflammatory Bowel Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>5</NO>
<PG>395-401</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:53:19 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035511"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-30 15:53:08 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>Wildt S, Munck LK, Vinther-Jensen L, Hansen BF, Nordgaard-Lassen I, Christensen S, et al</AU>
<TI>Treatment of collagenous colitis with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. A randomised, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>2005</YR>
<PG>OP-G-67</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:53:08 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035512"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 15:53:52 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035510"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-05 13:23:18 -0400" MODIFIED_BY="Tran M Nguyen">
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-2011" MODIFIED="2017-05-30 16:02:09 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Calabrese 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-30 13:54:37 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese C, Gionchetti P, Liguori G, Areni A, Fornarini GS, Campieri M, et al</AU>
<TI>Clinical course of microscopic colitis in a single-center cohort study</TI>
<SO>Journal of Crohn's &amp; Colitis</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>3</NO>
<PG>218-21</PG>
<IDENTIFIERS MODIFIED="2017-05-30 13:54:37 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035514"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 16:02:09 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delarive-1998" MODIFIED="2017-05-30 16:02:18 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Delarive 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-05-30 16:02:00 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delarive J, Saraga E, Dorta G, Blum A</AU>
<TI>Budesonide in the treatment of collagenous colitis</TI>
<SO>Digestion</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>4</NO>
<PG>364-6</PG>
<IDENTIFIERS MODIFIED="2017-05-30 16:02:00 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035516"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-30 16:02:18 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035515"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentile-2015" MODIFIED="2017-07-05 13:09:19 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Gentile 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-05 13:09:19 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, et al</AU>
<TI>Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2013</YR>
<VL>108</VL>
<NO>2</NO>
<PG>256-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035517"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mali-2015" MODIFIED="2017-01-16 12:46:26 -0500" MODIFIED_BY="Tran M Nguyen" NAME="Mali 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-01-16 12:46:26 -0500" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mali P, Komanapalli S, Kumar N</AU>
<TI>Role of maintenance steroids in microscopic colitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2015</YR>
<VL>110</VL>
<PG>S569</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035520"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035519"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke2014" MODIFIED="2017-05-30 13:54:58 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Miehlke2014" YEAR="2014">
<REFERENCE MODIFIED="2017-05-30 13:54:58 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Hansen JB, Madisch A, Schwarz F,Kuhlisch E, Morgner A, et al</AU>
<TI>Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy</TI>
<SO>Journal of Crohn's &amp; colitis</SO>
<YR>2014</YR>
<VL>8</VL>
<PG>S215-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035522"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035521"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taheri-2011" MODIFIED="2017-07-05 13:23:18 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Taheri 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-07-05 13:23:18 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taheri A, Sadighi A, Nikkhoo B, Farhangi E</AU>
<TI>Evaluation of effects and complications of probiotics in microscopic colitis, a double blind placebo control clinical trial</TI>
<SO>Gastroenterology</SO>
<YR>2011</YR>
<VL>140</VL>
<NO>5</NO>
<PG>S852</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7035524"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7035523"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-08 09:07:41 -0500" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-08 09:07:41 -0500" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Chande-2017" MODIFIED="2017-11-08 09:07:38 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2017" TYPE="COCHRANE_REVIEW">
<AU>Chande N, Al Yatama N, Bhanji T, Nguyen TM, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating lymphocytic colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2017-11-08 09:06:48 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-11-08 09:06:48 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD006096.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-1994" MODIFIED="2012-08-10 10:09:47 -0400" MODIFIED_BY="David J. Tsoulis" NAME="Greenberg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al</AU>
<TI>Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>13</NO>
<PG>836-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-1996" NAME="Greenberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al</AU>
<TI>Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>1</NO>
<PG>45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-05-30 16:10:52 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-926</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-05-30 16:09:49 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hjortswang-2009" MODIFIED="2017-05-30 16:09:43 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Hjortswang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hjortswang H, Tysk C, Bohr J, Benoni C, Kilander A, Larsson L, et al</AU>
<TI>Defining clinical criteria for clinical remission and disease activity in collagenous colitis</TI>
<SO>Inflammatory Bowel Diseases</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>1875-1881</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2017-05-30 16:09:32 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Schünemann 2011" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-03-08 08:01:12 -0500" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Chande-2002" MODIFIED="2017-03-08 07:58:01 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2002" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:58:01 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:58:01 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2003a" MODIFIED="2017-03-08 07:59:33 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2003a" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:59:07 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:59:07 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2003b" MODIFIED="2017-03-08 08:01:12 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2003b" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2017-03-08 08:01:12 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 08:01:12 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2004a" MODIFIED="2017-03-08 07:52:01 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2004a" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:52:01 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:52:01 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2004b" MODIFIED="2017-03-08 07:52:11 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Chande N, McDonald JWD, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis: A Cochrane Inflammatory Bowel Disease Group systematic review of randomized trials</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>12</NO>
<PG>2459-65</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15571596"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2005" MODIFIED="2017-03-08 07:48:30 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2005" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:48:08 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:48:08 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2006" MODIFIED="2017-03-08 07:46:14 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2006" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:46:14 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:46:14 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2008" MODIFIED="2017-03-08 07:41:00 -0500" MODIFIED_BY="John K MacDonald" NAME="Chande 2008" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating lymphocytic colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-03-08 07:41:00 -0500" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-03-08 07:41:00 -0500" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575.pub5"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-08 14:12:34 -0500" MODIFIED_BY="John K MacDonald">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-08 14:11:41 -0500" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-11-08 14:04:19 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Baert-2002">
<CHAR_METHODS MODIFIED="2017-11-08 12:50:32 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled. Duration of treatment was 8 weeks, plus an 8 week treatment-free follow-up, for a total of 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 13:59:16 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 28) aged &gt; 18 years with clinically and histologically confirmed active collagenous colitis</P>
<P>Clinical: minimum 3 semi-loose or loose stools per day for at least 8 weeks, no other significant cause on history/physical, negative stool examination for pathogens, parasites, and C. difficile toxin and no macroscopic inflammation on colonoscopy (and no other endoscopic findings other than diverticulosis or diminutive polyps). Histological: subepithelial collagen band &gt; 10 um thick and typical feathery appearance of the inferior border; increased mixed inflammatory cell infiltrate in lamina propria. Cases with overlapping features with lymphocytic colitis were allowed if the collagen band was a predominant finding</P>
<P>Patients with significant gastrointestinal disease (except controlled gastroesophageal reflux disease and celiac disease on a long-term gluten-free diet) were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 13:59:20 -0500" MODIFIED_BY="John K MacDonald">
<P>Budesonide (Budenofalk) 9 mg/day (n = 14) versus placebo (n = 14) for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:04:15 -0500" MODIFIED_BY="John K MacDonald">
<P>Proportion of patients achieving clinical and/or histological response</P>
<P>Clinical: reduction of stool frequency in last week of treatment by at least 50%.<BR/>Histological: statistically significant reduction of the infiltrate in the lamina propria and/or a significant reduction in the mean thickness of the collagen band<BR/>Other end-points were impact on abdominal pain, stool consistency score, patient's general well-being, amount of time necessary to induce remission, safety of budesonide, and long-term clinical effects of budesonide including the relapse rates after weaning or discontinuing budesonide</P>
<P>All patients kept a diary throughout the study period. Each patient underwent colonoscopy and standardized biopsy protocol pre- and post-treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:04:19 -0500" MODIFIED_BY="John K MacDonald">
<P>Data from first 8 weeks of the study only were included in the analysis, as this was the duration of treatment with active drug or placebo. Five patients that failed to meet the inclusion criteria after being randomized into the trial (upon review of their stool diaries) were excluded from the analysis. Medications that could possibly affect stool frequency or the natural history of the disease were not allowed during the study and were discontinued (with an appropriate wash-out period) before inclusion. Other chronic medications were allowed to be continued as long as the intake remained stable throughout the study period. 3 patients (2 placebo) dropped out of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:05:04 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bonderup-2003">
<CHAR_METHODS MODIFIED="2017-11-08 14:04:46 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled. Duration of study was 8 weeks. Stool frequency and stool weight was recorded pre- and immediately after stopping treatment. All patients underwent sigmoidoscopy with standardized biopsy protocol pre- and post-treatment. Randomization was performed by the drug company. Medication and placebo were delivered prepackaged with consecutive randomized numbers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:04:54 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 20, 16 females) aged &gt; 18 years with clinically and histologically confirmed active collagenous colitis</P>
<P>Clinical: &gt; 4 stools/day and/or stool weight &gt; 200 g/day averaged over 3 days pre-treatment. Negative stool samples for pathogens, parasites, and ova. Histological: collagen layer &gt; 10 um Inflammation was graded on a scale (0 to 3) independently by 2 pathologists</P>
<P>Patients with other chronic gastrointestinal diseases were excluded, as were those with clinically significant renal or hepatic disease, those who had been treated with anti-inflammatory drugs (aminosalicylates, corticosteroids, azathioprine) in the previous 3 months or were pregnant or breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:04:56 -0500" MODIFIED_BY="John K MacDonald">
<P>Budesonide (9 mg/day for 4 weeks, 6 mg for 2 weeks and 3 mg for 2 weeks) versus placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:05:01 -0500" MODIFIED_BY="John K MacDonald">
<P>Primary outcome was the proportion of patients that achieved a clinical or histological response </P>
<P>Clinical: reduction of stool frequency and/or stool weight by &gt; 50%<BR/>Histological: decrease in inflammation grade or reduction in thickness of the collagen layer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:05:04 -0500" MODIFIED_BY="John K MacDonald">
<P>No antiinflammatory drug treatment was allowed during the study period or for 3 months prior to inclusion. During the study antidiarrheal medications were allowed except during the periods of stool sampling. During these periods no other treatments with effects on the GI tract were allowed. NSAIDS were not permitted, but other chronic medications (e.g. - antihypertensives) were allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:05:45 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bonderup-2009">
<CHAR_METHODS MODIFIED="2017-11-08 14:05:19 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled. Randomization was done with a computerized randomization program in blocks of 4 patients</P>
<P>Induction: 6 weeks</P>
<P>Maintenance: 24 weeks</P>
<P>Treatment-free follow-up: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:05:24 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 42) aged &gt; 18 years with clinically (&gt; 3 stools/day over 3 days registration) and histologically (subepithelial collagen layer with a thickness &gt; 10 um, inflammation of the lamina propria, and a lymphocytic infiltrate of the epithelium) confirmed active collagenous colitis plus negative faecal cultures for intestinal pathogens</P>
<P>Induction: n = 42</P>
<P>Maintenance: n = 34, 17 in each arm</P>
<P>Follow-up: n = 15, 13 in the budesonide arm and 2 in the placebo arm</P>
<P>Patients were excluded if they had been treated with salazopyrine, 5-aminosalicylic acid, budesonide or a systemic glucocorticoid within 3 months of trial enrolment or treated with ketoconazole during the 7 days before random selection. Other exclusionary criteria were other chronic gastrointestinal diseases (including celiac disease), clinically relevant impairment of kidney or liver function, previous intestinal resection or stoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:00:10 -0500" MODIFIED_BY="John K MacDonald">
<P>Induction: 6 weeks, open-label 9 mg/day budesonide, randomized to maintenance or placebo therapy</P>
<P>Maintenance: 24 weeks, budesonide 6 mg/day versus placebo</P>
<P>Treatment-free follow-up: 24 weeks</P>
<P>Patients who relapsed during the maintenance or follow-up were offered treatment with open-label budesonide (9 mg/day for 6 weeks, followed by budesonide 6 mg/day for 24 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:05:42 -0500" MODIFIED_BY="John K MacDonald">
<P>Induction: proportion entering clinical/histological remission, randomized to maintenance or placebo therapy after 6 weeks</P>
<P>Maintenance: proportion maintaining clinical/histological remission after 24 weeks</P>
<P>Treatment-free follow-up: proportion maintaining clinical/histological remission 24 weeks</P>
<P>Clinical remission was defined as mean stool frequency of &lt; 3 per day</P>
<P>*Each patient underwent colonoscopy or sigmoidoscopy pre-treatment. All were scheduled to undergo sigmoidoscopy at relapse or at the end of treatment, but this was only performed in 21 patients<BR/>Other outcome measures included: fecal weight (g/day), safety data, maintained histological response (collagen layer &lt;10 um and inflammation score &lt;1), the time to relapse and the rate of relapse after stopping treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:05:45 -0500" MODIFIED_BY="John K MacDonald">
<P>Data from the 24 weeks of the study only were included as the primary outcome measure, as this was the duration of active treatment with budesonide or placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:06:30 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Calabrese-2007">
<CHAR_METHODS MODIFIED="2017-11-08 14:06:04 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, unblinded, open-label study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:06:14 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 819) who presented to clinic, underwent a colonoscopy because of chronic watery diarrhoea and were diagnosed with microscopic colitis (aged 19&#8211;68 years; n = 64; 23 with collagenous colitis and 41 with lymphocytic colitis)</P>
<P>Clinical components of diagnosis: Chronic or recurrent non-bloody diarrhea<BR/>Histological components of diagnosis: Increased chronic inflammatory infiltrate (plasma cells, lymphocytes, eosinophils) in the lamina propria; increased number of intraepithelial lymphocytes, damage to surface epithelium, with flattening of epithelial cells and/or epithelial loss and detachment and minimal crypt architecture distortion; specific to the diagnosis of collagenous colitis was a subepithelial collagen band &gt;10 um thick, which entraps superficial capillaries, with an irregular lacy appearance at the lower edge of the basement membrane<BR/>"Patients with a clear correlation between symptoms and [consumption] of drugs (e.g. NSAIDS, ticlopidine, PPI) were excluded"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:06:18 -0500" MODIFIED_BY="John K MacDonald">
<P>Mesalazine 800 mg po tid (n = 20 with lymphocytic colitis and 11 with collagenous colitis) vs. mesalazine 800 mg po tid + cholestyramine 4 g po od (n = 21 with lymphocytic colitis and 12 with collagenous colitis) for 6 months</P>
<P>A 24-month treatment free follow was also performed</P>
<P>A second round of 6 month-therapy was offered if patients relapsed in follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:06:27 -0500" MODIFIED_BY="John K MacDonald">
<P>Primary outcomes:</P>
<P>Clinical response: "Complete response was complete resolution of diarrhoea. Partial response was improvement but not resolution of diarrhoea<BR/>Histological response: Normalization of histologic pattern at the end of 6 months</P>
<P>Secondary outcomes:</P>
<P>24-month follow-up with coloscopies and biopsies, annually; adverse events; and days to remission or relapse, as well as various lab data (routine blood biochemistry and hematological counts, C-reactive protein, antinuclear antibodies blood assay, serum T4 and thyroid stimulating hormone; IgA-IgG antigliadin, antiendomysium, IgG anti tTG antibody blood assays; and parasitic-bacterial, fecal-stool, and hemo-occult test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:06:30 -0500" MODIFIED_BY="John K MacDonald">
<P>"Relapse was defined as stool frequency greater than three soft or liquid stools per day"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:06:53 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Fine-1999">
<CHAR_METHODS MODIFIED="2017-11-08 14:06:43 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled. Duration of study was 8 weeks. After 8 weeks, placebo group remained blinded and crossed over to active treatment with bismuth salicylate</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:06:46 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 14, split evenly) with microscopic colitis (11F, 3M; aged 35-78 years; 9 with thickened subepithelial collagen, 5 without)</P>
<P>Clinical: 8 weeks of non bloody watery diarrhea (without steatorrhea) and normal endoscopic appearance of the colonic mucosa.<BR/>Histological (including involvement of the distal colon): excess mononuclear inflammatory cells in the lamina propria and surface epithelium without significant neutrophilia or eosinophilic inflammation, numerous crypt abscesses, or granuloma; and no other evidence of Crohn's disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 12:50:41 -0500" MODIFIED_BY="John K MacDonald">
<P>Bismuth subsalicylate (nine 262 mg/day chewable tablets in 3 divided doses) versus placebo (identically coloured and flavoured sucrose tablets) for 8 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:06:50 -0500" MODIFIED_BY="John K MacDonald">
<P>"48 hour fecal weight and consistency, and distal colonic histology (from 16 biopsies obtained by flexible sigmoidoscopy)" were assessed pre and post therapy</P>
<P>Clinical: improvement of diarrhea to passage of 2 or less formed or semi-formed stools/day<BR/>Histological: improvement of histopathology score by at least 50%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:06:53 -0500" MODIFIED_BY="John K MacDonald">
<P>Only patients with a thickened subepithelial collagen band on biopsy were included (scored as normal, focally thickened, or diffusely thickened). 4 patients with normal thickness of the subepithelial collagen band were excluded from the analysis. Patients were not to take antibiotics or anti-inflammatory agents for minimum 6 weeks, and not to take antidiarrheals for minimum 2 weeks prior to the beginning of the study</P>
<P>Abstract publication</P>
<P>For the histological outcome analysis, a histopathology score from 0 to 10 was based on the following parameters: surface epithelium assessed for micro-ulceration, cell flattening, and mucin depletion (scored: 0 - normal, 1 - moderate, 2 - severe); crypts (scored: 0 - normal, 1 - distorted architecture and/or cryptitis with neutrophils, 2 - containing crypt abscesses); lamina propria cellularity (scored: 0 - normal, 1 - focally increased with neutrophils, mononuclear inflammatory cells, or both, 2 - diffusely increased with neutrophils, mononuclear inflammatory cells, or both); number of intraepithelial lymphocytes within surface epithelium (scored 0 - normal, 1 - moderately increased, 2 - significantly increased); number of intraepithelial lymphocytes within crypt epithelium (scored 0 - normal, 1 - moderately increased, 2 - significantly increased)</P>
<P>Additional information provided by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:07:32 -0500" MODIFIED_BY="John K MacDonald" NOTES="&lt;p&gt;&lt;span class=&quot;inserted&quot; modified=&quot;2015-08-19 11:58:00 -0400&quot; modified_by=&quot;Petrease  H Patton&quot;&gt;The description of the hist&lt;/span&gt;&lt;span class=&quot;inserted&quot; modified=&quot;2015-08-19 11:59:00 -0400&quot; modified_by=&quot;Petrease  H Patton&quot;&gt;ologic outcomes are those listed in Miehlke 2002, not Madisch 2007. I am not sure why they appear in both tables&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-11-08 14:07:32 -0500" NOTES_MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Madisch-2007">
<CHAR_METHODS MODIFIED="2017-11-08 14:07:03 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled trial performed at multiple German centres. Duration of study was 6 weeks. Study had potential crossover for the non-responders in the placebo group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:07:11 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 31) aged 18-80 years with clinically and histologically confirmed collagenous colitis ("at least five liquid or soft stools per day on average per week, and a complete colonoscopy performed within the last 4 weeks before randomization")<BR/>
</P>
<P>Histological diagnosis made with colonoscopy with biopsy: main criteria was collagen band &gt; 10 um thick </P>
<P>Other analyzed criteria included inflammation of lamina propria (semi-quantitative definition) and degeneration of surface epithelium (qualitative definition)<BR/>Patients were excluded if they had other endoscopically or histologically verified causes for diarrhea, infectious diarrhea, pregnancy or lactation, previous colonic surgery, or known intolerance to <I>Boswellia serrata</I> extract. Patients who had received therapy within 4 weeks of randomization were also excluded if therapies included budesonide, salicylates, steroids, prokinetics, antibiotics, ketoconazole, or non-steroidal anti-inflammatt ory drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:07:13 -0500" MODIFIED_BY="John K MacDonald">
<P>
<I>Boswellia serrata</I> extract (three 400 mg/day capsules) versus placebo for 6 weeks</P>
<P>Cross-over therapy offered to non-responders after 6 weeks, open-labelled BSE 400 mg po t.i.d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:07:26 -0500" MODIFIED_BY="John K MacDonald">
<P>Primary endpoint was clinical remission after 6 weeks (stool frequency of &lt; 3 per day)</P>
<P>stool frequency of less than 3 per day<BR/>Secondary endpoints were histological changes and quality of life</P>
<P>Histological (via colonoscopy with biopsy): improvement in baseline parameters<BR/>Quality of life: assessed with SF-36 surveys at the beginning and at the end of 6 weeks of therapy</P>
<P>"Stool frequency and consistency, intake of study medication, adverse events, and any intake of allowed concomitant medication were assessed by standardized questionnaire"</P>
<P>"Patients who did not respond to treatment after 6 weeks were individually unblinded. If they were in the active treatment group, they were judged as treatment failure. If they were in the placebo group, crossover therapy with open-labelled BSE 400 mg, given orally three times daily was offered"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:07:32 -0500" MODIFIED_BY="John K MacDonald">
<P>During the first three weeks of treatment loperamide was allowed as rescue medication. "Patients were allowed to use butylscopolamine in case of abdominal pain"</P>
<P>Steroids, anti-inflammatory drugs, immunosuppressives, antibiotics, prokinetics and bismuth compounds were not allowed during the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:08:18 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Miehlke-2002">
<CHAR_METHODS MODIFIED="2017-11-08 14:07:47 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled performed at 35 centres in Germany (hospitals and private clinics), which used a centrally-removed pathologist. Duration of study was 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:07:58 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 51) aged 18-80 years with clinically and histologically confirmed collagenous colitis ("at least five liquid or soft stools per day on average per week, and a complete colonoscopy performed within the last 4 weeks before randomization"). Female patients must also be using appropriate contraception</P>
<P>Histological diagnosis made with colonoscopy with biopsy: main criteria was collagen band &gt; 10 um thick by Van Giesen staining. Other analyzed criteria included inflammation of lamina propria (semi-quantitative definition) and degeneration of surface epithelium (qualitative definition)<BR/>
</P>
<P>Patients were excluded if they had evidence of infectious diarrhea (from culture or biopsy), any other endoscopic or histologic findings (polyps 2 cm, tumors, Crohn&#8217;s disease, ulcerative colitis, ischemic colitis) which may have caused diarrhea, known intolerance to budesonide, pregnancy, lactation, or prior partial colonic resection, or if they had received treatment with budesonide, salicylates, steroids, prokinetics, antibiotics, ketoconazole, or non-steroidal anti-inflammatory drugs within 4 weeks before randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:08:01 -0500" MODIFIED_BY="John K MacDonald">
<P>Budesonide 9 mg/day (three 3 mg/day tablets once in the morning) versus identically-matched placebo for 6 weeks</P>
<P>Cross-over therapy offered to non-responders after 6 weeks, open-label budesonide, 9 mg/day po for another 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:08:15 -0500" MODIFIED_BY="John K MacDonald">
<P>Proportion of patients achieving clinical remission or histological improvement after 6 weeks</P>
<P>Clinical remission defined as: average of &lt; 3 soft stools per day during the last week of treatment<BR/>Histological (via colonoscopy with biopsy): change of 2 of 3 of the following parameters: collagen band thickness no more than 10 um or reduced to 50% compared to baseline; improvement of inflammation of the lamina propria; improvement of degeneration of surface epithelium<BR/>Patients also recorded daily stool frequency and consistency, "intake of the study medication, any side effects, and any intake of allowed concomitant medication"</P>
<P>Patients who did not respond to treatment after 6 weeks were unblinded. If they were in the active treatment group, they were judged as treatment failure. If they were in the placebo group, crossover therapy with open-label budesonide, 9 mg/day po for another 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:08:18 -0500" MODIFIED_BY="John K MacDonald">
<P>Other therapies for collagenous colitis were discontinued for at least 3 weeks prior to enrolment in the trial. Loperamide was allowed for the first 4 weeks of the trial (used by 4 patients in the placebo group and 2 in the budesonide group), but no anti-diarrhoeals allowed in the last two weeks. Patients were allowed to use butylscopolamine for abdominal pain</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:08:39 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Miehlke-2008">
<CHAR_METHODS MODIFIED="2017-11-02 09:58:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled performed at 38 centres in Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:08:28 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients aged &gt;18 years with symptomatic and histologically proven collagenous colitis</P>
<P>Clinically active defined as "&gt;3 watery/loose stools per day on &#8805; 4 of the previous 7 days and had a history of diarrhoea for &#8805; 4 weeks"</P>
<P>Histological requirements: Subepithelial collagen band &gt; 10 um; inflammatory infiltrate in the lamina propria</P>
<P>Exclusion criteria: infectious causes for diarrhea; other inflammatory bowel diseases; history of colonic surgery; celiac disease; malignancies; severe concomitant (organ) diseases that would interfere with the study; at time of inclusion, were being treated 5-aminosalicylates, salicylates (except in doses &#8804;165 mg for cardiovascular prophylaxis), systemic steroids, antibiotics, or NSAIDs (including selective cyclo-oxygenase-2 inhibitors); used of budesonide within the 2 weeks prior to enrolment, known intolerance to budesonide; pregnancy, lactation, drug and/or alcohol abuse</P>
<P>Induction phase: n = 48</P>
<P>Maintenance phase: n = 46, split equally to budesonide and placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:08:32 -0500" MODIFIED_BY="John K MacDonald">
<P>Induction phase: open-label budesonide 9 mg/day (3 x 3 mg capsules [Entocort CIR capsules]) once/day for 6 weeks (all included patients)</P>
<P>Maintenance phase: budesonide 6 mg/day or placebo for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:08:38 -0500" MODIFIED_BY="John K MacDonald">
<P>Primary endpoint was cumulative rate of relapse at the end of 6 months (maintenance phase); remission had been induced during the 6 week induction phase. Relapse was defined as &gt; 3 stools per day on &#8805; 4 consecutive days. Relapse rates were determined from daily patient diaries</P>
<P>Secondary outcomes were time to relapse during maintenance therapy; the proportions of patients with clinical remission after 6 weeks&#8217; induction therapy and after 2 and 4 months of maintenance therapy; HRQOL outcomes; and changes in histologic variables after 6 months&#8217; maintenance therapy ("thickness of the collagen band (&gt;10 or &lt;10 µm); inflammation of the lamina propria (infiltration with lymphocytes and plasma cells; absent, mild, moderate, or severe); and degeneration of the surface epithelium (absent, or present)"). Histologic improvement defined as improvement in &#8805; 2 variables versus baseline<BR/>
</P>
<P>Safety and tolerability assessments were also performed<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:08:39 -0500" MODIFIED_BY="John K MacDonald">
<P>HRQOL was assessed using the validated Medical Outcome Short Form (SF)-36 questionnaire26 and the Short Inflammatory Bowel Disease Questionnaire (sIBDQ)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:09:24 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Miehlke-2014">
<CHAR_METHODS MODIFIED="2017-11-08 14:09:06 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, double-dummy, placebo-controlled, comparative phase-3 trial performed at 31 European centres (hospitals and private clinics) - Germany, Denmark, Lithuania, Spain, and the United Kingdom. Duration of study was 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:09:14 -0500" MODIFIED_BY="John K MacDonald">
<P>N = 92 (budesonide n = 30; mesalamine n = 25, placebo n = 37)</P>
<P>Inclusion criteria:</P>
<P>Clinical: Patients between 18 and 80 years of age with &gt;4 watery or soft stools on &#8805;4 days and &gt;3 stools/day in the week prior to baseline. Patients must have also had chronic diarrhoea for &#8805;3 months prior to baseline and have had a colonoscopy within 4 months of baseline</P>
<P>Histological: confirmed collagenous colitis with subepithelial collagenous band &gt; 10 um and degeneration of the surface epithelium</P>
<P>Exclusion criteria: "other significant colonic diseases (i.e. polyps &gt;2 cm, tumors, Crohn&#8217;s disease, ulcerative colitis, ischemic colitis), partial colonic resection, infectious diarrhea, celiac disease (blood tests and/or duodenal histology required), diarrhea caused by other organic diseases of the gastrointestinal tract, treatment with budesonide, <I>Boswellia serrata</I> extract, salicylates, steroids, antibiotics, cholestyramine, nonsteroidal anti-inflammatory, or other immunosuppressant drugs within the last 4 weeks before baseline, malignant disease, severe comorbidity, abnormal hepatic function or liver cirrhosis, renal insufficiency, active peptic ulcer disease, known intolerance or resistance to study drugs, pregnancy, or breast-feeding"<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 15:41:22 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Budesonide 9 mg/day ["(3x3 mg pH-modified release capsules, Budenofalk) 30 minutes before breakfast"]</P>
<P>Mesalamine 3 g/day [morning dosage of "sachets each containing 1.5 g mesalamine presented as a granule formulation, Salofalk"]</P>
<P>Placebo</P>
<P>All medications take for 8 weeks if responsive. If unresponsive after 4 weeks, or relapsed in the 16 week treatment-free follow-up, patient's removed from study arm and received 9 mg/day of budesonide for the remaining 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:09:24 -0500" MODIFIED_BY="John K MacDonald">
<P>Measured at each interim visit: 2, 4, 6, 8 weeks; 8 and 16 weeks</P>
<P>Primary Outcomes:</P>
<P>Clinical: remission defined as &#8804;3 stools/day in the week before the visit.</P>
<P>Histological: measured collagen band thickness (&#8804;10um or 50% reduction), lamina propria inflammation (by scoring), intraepithelial lymphocytes (by scoring) and whether the surface epithelium was degenerated. Improvement was defined as improvement of two of the parameters. Histological remission was defined as "collagen band thickness 10 mm and no inflammation of the lamina propria with neutrophilic and eosinophilic granulocytes."</P>
<P>Secondary Outcome:</P>
<P>Clinical remission was also evaluated according to Hjortswang-Criteria of disease activity ("mean &lt;3 stools per day, with &lt;1 watery stool per day)"</P>
<P>Also, "time to remission, number of watery and solid stools per week, abdominal pain, histopathology,<BR/>tolerability and safety, symptom relapse during treatment-free follow-up, and response to open-label budesonide"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-18 15:41:22 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Relapse was defined as: "&gt;4 watery/soft stools on at least 4 days in the week before the visit and &gt;3 stools per day within the last 7 days before the visit"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:10:13 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Munch-2016">
<CHAR_METHODS MODIFIED="2017-11-08 14:09:39 -0500" MODIFIED_BY="John K MacDonald">
<P>An initial 8-week open-label induction phase with budesonide therapy to achieve clinical remission was followed by a double-blind, randomized, placebo-controlled, parallel-group, multicentre, 12-month phase for maintenance of clinical remission. After this there was 6 months of treatment-free follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:09:54 -0500" MODIFIED_BY="John K MacDonald">
<P>A total of 148 patients were screened, all age &#8805; 18 years</P>
<P>Inclusion criteria:<BR/>
</P>
<P>1. Histologically established diagnosis of collagenous<BR/>colitis, defined as thickened subepithelial collagen layer &#8805;10 mm on well-orientated sections, and increased inflammatory cells indicating chronic inflammation in the lamina propria</P>
<P>2. Prescreening history of non-bloody, watery diarrhea for &#8805;2 weeks in patients with newly diagnosed collagenous colitis, or a prescreening history of clinical relapse for &#8805;1 week in patients with previously established collagenous colitis</P>
<P>3. A mean of &#8805;3 stools/day, including a mean of &#8805;1 watery stool/day, during the week prior to baseline</P>
<P>Exclusion criteria:</P>
<P>1. Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease or hypertension if careful medical monitoring was not ensured</P>
<P>2. Established cataract</P>
<P>3. Known hereditary problems of galactose or fructose intolerance, lactase deficiency, increased levels of anti-transglutaminase 2 antibodies</P>
<P>4. Established osteoporosis with T-score &lt;&#8722;2.5</P>
<P>As per Figure 2:</P>
<P>110 met eligibility criteria and started the open-label phase. 92 patients had achieved remission during the open-label phase and were randomized for treatment in the double-blind phase (44 budesonide, 48 placebo). 43 completed the 12-month study visit (32 budesonide, 11 placebo). 36 patients at the end of the double-blind phase (28 budesonide, 8 placebo) entered the follow-up phase</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:10:02 -0500" MODIFIED_BY="John K MacDonald">
<P>During the open-label induction phase, all patients received once-daily budesonide (Budenofalk 3 mg capsules) at a dose of 9 mg/day for 4 weeks, then 6 mg/day for 2 weeks, followed by alternate daily doses of 6 and 3 mg/day (mean 4.5 mg/day) for the final 2 weeks</P>
<P>During the double-blind phase, the active treatment group received once-daily budesonide 6 and 3 mg/day on alternate days (mean 4.5 mg/day). The placebo group received two placebo capsules and one placebo capsule on alternate days, administered once daily</P>
<P>After the final visit of the double-blind phase (month 12), there was a 2-week tapering-off period, during which patients in the active treatment group received 3 mg/day budesonide for 1 week followed by 3 mg/day budesonide every second day for 1 week. Patients in the placebo group received one placebo capsule on the corresponding days</P>
<P>Patients who remained in clinical remission at the end of the double-blind phase received no further study drug after the 2-week tapering-off period</P>
<P>During the treatment-free follow-up, no intervention was given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:10:09 -0500" MODIFIED_BY="John K MacDonald">
<P>The primary endpoint was the proportion of patients remaining in clinical remission during the 12-month double-blind phase, with clinical remission defined as a mean of &lt;3 stools/day, including a mean of &lt;1 watery stool/day over 1 week</P>
<P>The main secondary endpoints during the double-label phase included health-related quality of life using the Short Health Scale (SHS) and the Psychological General Well-Being Index (PGWBI)</P>
<P>Further secondary endpoints during the double-blind phase were achievement of histological remission or histological improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:10:13 -0500" MODIFIED_BY="John K MacDonald">
<P>During the entire study period, loperamide, anti-inflammatory or immunosuppressant drugs were not permitted<BR/>Prophylactic treatment of osteoporosis with calcium and vitamin D3 was strongly recommended and under the responsibility of the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:10:47 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Munck-2003">
<CHAR_METHODS MODIFIED="2017-11-08 14:10:24 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled, multi-centred trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:10:35 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 12, 11 with collagenous colitis and 1 with lymphocytic colitis) aged &gt;18 years reporting at least 3 months with diarrhoea without blood or pus and with a stool volume &#8805;350 g/day or &#8805;200 g/day and a stool frequency &#8805;5/day and a histological diagnosis of microscopic colitis. Female patients also needed to use appropriate contraceptive techniques</P>
<P>Patients were diagnosed histologically using a macroscopic normal colonoscopy or sigmoidoscopy plus a normal barium enema and confirmed by an independent pathologist with either lymphocytic colitis or collagenous colitis using the following criteria: &#8220;chronic inflammatory infiltrate in the lamina propria and either a lymphocytic infiltration of at least 20% of epithelial crypt cells (lymphocytic colitis) and/or a subepithelial collagen bond &gt;10 µm in a well-oriented biopsy (collagenous colitis)&#8221;</P>
<P>Excluded patients: tested positive for pathogenic bacteria or parasites; failed a normal lactose absorption test and vitamin B12 absorption test, or a normal barium follow through; had celiac disease (confirmed with IgG and IgA antigliadin antibodies and antiendomysium antibodies and/or abnormal histology in duodenal biopsies); had bile acid malabsorption and/or no response to cholestyramine, and/or steatorrhoea; had other gastrointestinal diseases or previous gastrointestinal surgery (exception: cholecystectomy); had other serious diseases, abnormal laboratory tests (haematology, renal function, liver enzymes, urinalysis); had been treated with immunosuppressives within 3 months of randomization; or used medicines with known effects on gastrointestinal functioning including anti-ulcer medication, antacids, antibiotics and NSAIDs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:10:36 -0500" MODIFIED_BY="John K MacDonald">
<P>Prednisolone, n = 9 (50 mg/dayfor 2 weeks, tapered to 37.5 mg/day in third week) versus placebo, n = 3, for 2 weeks. All patients also received Ca 500 mg + vitamin D 5 ug/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:10:43 -0500" MODIFIED_BY="John K MacDonald">
<P>Proportion of patients achieving clinical remission after 2 weeks</P>
<P>Clinical remission was defined as stool weight &#8804; 200 g/day or frequency &#8804; 2/day; effect was defined as &gt;50% reduction of either stool frequency or weight.<BR/>Side effects were also recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:10:47 -0500" MODIFIED_BY="John K MacDonald">
<P>Inclusion of patients was stopped when planned monitoring indicated that prednisone did not induce remission. Protocol also included a 48-week azathioprine continuation phase which was closed when it became clear that the calculated number of patients could not be recruited</P>
<P>Medications with immunosuppressive effects, antidiarrhoeals or those with known effects on gastrointestinal function were not allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 14:11:28 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Wildt-2006">
<CHAR_METHODS MODIFIED="2017-11-08 14:11:02 -0500" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo-controlled trial at 4 Danish centres. Randomization was in a 2:1 fashion (probiotic:placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:11:13 -0500" MODIFIED_BY="John K MacDonald">
<P>Patients (n = 36*, therefore n = 29, 2 men) aged &#8805;18 years with confirmed histological diagnosis of collagenous colitis that is active and untreated for at least 4 weeks prior to study inclusion.</P>
<P>Clinically active disease is defined as &gt; 21 liquid or soft stools per week or stool weight of &gt; 200 g/day for at least 4 weeks<BR/>Histological diagnosis required "a subepithelial collagen band &gt; 10 um in a well oriented section of the mucosa and inflammation of the lamina propria with infiltration of predominantly lymphocytes and plasma cells"<BR/>Exclusion criteria included: pregnancy or breast feeding, chronic liver or kidney disease, severe vascular or cardiopulmonary disease, malignancy, immunosuppressive disease or treatment, known inflammatory bowel disease besides collagenous colitis (including celiac disease), evidence of infectious diarrhea, prior gastrointestinal surgery other than appendectomy, and malabsorption syndromes. Treatment with aminosalicylates, antibiotics, cholestyramine, nonsteroidal anti-inflammatory drugs, and steroids was not allowed 4 weeks prior to study entrance</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:11:16 -0500" MODIFIED_BY="John K MacDonald">
<P>Probiotic (AB-Cap-10; two capsules twice daily) or placebo (2 capsules twice daily) for 12 weeks. Loperamide and opioids were allowed during the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:11:22 -0500" MODIFIED_BY="John K MacDonald">
<P>Primary outcome was the proportion of patients with a at least a 50% reduction in the number of stools per week at 12 weeks<BR/>Secondary outcomes: changes in bowel frequency, stool consistency, stool weight, abdominal pain and bloating, histopathology scores from biopsies, Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores, use of antidiarrhoeal medication, and adverse events</P>
<P>Histological scores from: significant change in three parameters: reduction of thickness of the collagen band; improvement in the degree of inflammation of the lamina propria; improvement of degeneration of surface epithelium<BR/>
</P>
<P>The study period was 17 weeks (12 weeks treatment + 5 weeks follow up) with patients being assessed at weeks -1, 0, 4, 6, 12, and 16. All patients kept a diary throughout the study period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 14:11:28 -0500" MODIFIED_BY="John K MacDonald">
<P>AB-Cap-10 is a mixture of L. acidophilus strain LA-5 and B. animalis subsp. lactis strain BB-12. Each capsule contained 0.5 x 10^10 colony-forming units of each bacterium, leading to a total delivery of 1 x 10^10 CFU per capsule</P>
<P>SIBDQ; a 10-item questionnaire measuring health-related quality of life [HRQOL] intended for patients with Crohn&#8217;s disease and ulcerative colitis</P>
<P>*Seven patients that failed to meet the inclusion criteria after being randomized into the trial (six patients had lymphocytic colitis and one had a subepithelial collagen band &lt; 10 um thick) are excluded from the analysis<BR/>Study enrolment was stopped early due to difficulties recruiting patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-08 14:12:34 -0500" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-11-08 14:11:44 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Calabrese-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-08 14:11:44 -0500" MODIFIED_BY="John K MacDonald">
<P>Not a randomized trial. It was a cohort extension trial of another randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-08 14:11:45 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Delarive-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-08 14:11:45 -0500" MODIFIED_BY="John K MacDonald">
<P>Not a randomized trial. It is a case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-08 14:12:13 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Gentile-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-08 14:12:13 -0500" MODIFIED_BY="John K MacDonald">
<P>Not a randomized trial. It also included microscopic colitis patients without specifying for collagenous colitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-08 14:12:29 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Mali-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-08 14:12:29 -0500" MODIFIED_BY="John K MacDonald">
<P>Not a randomized trial. It also included microscopic colitis patients without specifying for collagenous colitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-08 14:12:34 -0500" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Miehlke2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-08 14:12:34 -0500" MODIFIED_BY="John K MacDonald">
<P>Withdrawal of short-term budesonide therapy. Examines different outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-05 13:23:38 -0400" MODIFIED_BY="Tran M Nguyen" STUDY_ID="STD-Taheri-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-05 13:23:38 -0400" MODIFIED_BY="Tran M Nguyen">
<P>No study data </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-11-08 14:11:41 -0500" MODIFIED_BY="John K MacDonald">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-08 14:11:29 -0500" MODIFIED_BY="John K MacDonald" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:36 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>The method of randomization was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:05:07 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>Not described in published study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-18 11:28:54 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>Quote: "Computer-generated block randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:06:33 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Randomization was performed with a computer generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:42 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>"Randomization was performed by pulling pieces of paper out of a sealed box"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:07:36 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>Randomization was via a central computer generated randomization list in groups of four patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:45 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>"Eligible patients were randomized by groups of 4 patients according to a central computer-generated randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:02:20 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>Method of randomization not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-18 15:41:28 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>Computer generated random numbers assigning at a 1:1:1 ratio between the 3 arms of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:47 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>Method of randomization was described as "a computer-generated randomisation list using randomly permuted blocks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:10:51 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>Method of randomization not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:11:29 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>Randomization was completed in blocks of 9 using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-08 14:11:30 -0500" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:36 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>Randomization was done centrally by the company delivering the drugs and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:37 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>Randomization was performed centrally by the drug company</P>
<P>Medication and placebo were delivered prepackaged with consecutive randomized numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:05:48 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>Allocation sequence appears to be centrally generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-18 11:29:33 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="UNKNOWN" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Not described in published study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:42 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Not described in abstract publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-18 11:29:57 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>Quote: "central computer-generated randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:46 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:08:43 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>Method of allocation not described in published study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:09:28 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>Computer generated, random numbers list prepared by a contract research organization that had no clinical involvement with the trial</P>
<P>Used medication packed in boxes with consecutive numbers according to the randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:10:16 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>Allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-18 15:41:52 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="UNKNOWN" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>Method of allocation not described in published study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:11:30 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>Method of randomization not described in study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-11-08 14:11:32 -0500" MODIFIED_BY="John K MacDonald" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-18 11:29:09 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="UNKNOWN" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "All biopsies were randomly read by 2 blinded expert pathologists"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:05:14 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "The placebo medication was identical in appearance"</P>
<P>Quote: "Histopathological evaluation was performed blindly by the two pathologists"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:05:51 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "budesonide 6 mg once a day (2 x 3 mg capsules) or matching placebo"</P>
<P>Quote: "blinded follow-up period (the randomisation code was unbroken until completion of follow-up, such that neither patients nor physicians knew which treatment the patient had received during maintenance therapy)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:06:36 -0500" MODIFIED_BY="John K MacDonald" RESULT="NO" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Quote: "open-label"</P>
<P>Quote: "All biopsies were analyzed by a single experienced pathologist in a blinded fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 12:50:43 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "identically coloured and favoured sucrose-placebo tablets"</P>
<P>Quote: "Blind histologic analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-19 10:23:35 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "Physicians, patients, and pathologist were blinded to the treatment group. Study medication was provided in identical- looking white boxes labelled with consecutive numbers corresponding to the randomization list. In addition, the placebo containers were prepared from the inside to mimic the typical scent of incense to prevent unblinding by the typical odour of BSE."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 12:50:46 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "Active and placebo capsules were identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-18 11:30:17 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "budesonide and placebo capsules appeared identical and were packaged in identical bottles"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:09:30 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>"double-blind, double-dummy"</P>
<P>Identical placebo capsules and sachets</P>
<P>Single pathologist was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:10:18 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>Double-blinding is mentioned, but not described in more detail. Placebo capsules were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-18 11:30:34 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "identical placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-08 14:11:32 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>Quote: "double-blind"</P>
<P>Quote: "Placebo medication (Chr. Hansen A/S) was identical in appearance, size, and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-08 14:11:37 -0500" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:04:37 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>Quote: "All calculations were made on an intention-to-treat basis"</P>
<P>Quote: "Three patients dropped out of the study (2 placebo), one for noncompliance and 2 because of treatment failure"</P>
<P>Intention-to-treat was followed for clinical response</P>
<P>Intention-to-treat was not followed for histologic response (denominators of 13 and 12 for the treatment and placebo group respectively)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:50:37 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>No description of dropouts or withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:05:58 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>Quote: "All analyses were completed on an intention-to-treat basis; premature discontinuation of treatment was considered as relapse in both treatment arms"</P>
<P>Quote: "Two patients, one in each group, discontinued maintenance treatment because of adverse events"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:50:40 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P/>
<P>3 of 23 patients with collagenous colitis were lost to follow-up over a 24 month period </P>
<P>The treatment groups and reasons for the missing data were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-18 11:29:47 -0400" MODIFIED_BY="Petrease  H Patton" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Quote: "All patients taking BSS completed the study; one patient receiving placebo dropped out of the study after 4 weeks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:07:41 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>5/31 patients discontinued (4 patients, reasons described) the trial or were lost to follow-up (1 patient). All 31 patients were included in the intention-to-treat analysis, 26 patients were included in the per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:50:47 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>6/51 patients withdrew (3 from placebo and 3 from budesonide) from the trial (reasons described)</P>
<P>Both per-protocol and intention-to-treat analysis available</P>
<P>For endoscopic investigations per-protocol analysis used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:09:00 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>21/46 patients withdrew during the maintenance phase, 17 due to relapse (14 taking placebo and 3 taking budesonide), 4 due to adverse events (1 taking placebo and 3 taking budesonide)</P>
<P>Quote: "for the purposes of intention-to-treat analysis, patients who withdrew because of adverse events during maintenance therapy were counted as relapses"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:09:32 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>21/92 patients withdrew from the trial prematurely (before 8 weeks). Two taking budesonide, 9 taking mesalamine and 10 taking placebo. Reasons described. 64/92 entered follow up, 16 entered open-label budesonide. Intention-to-treat was followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:10:19 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>Well described patient disposition in Figure 2 and had intention-to-treat analysis described. They accounted for attrition/exclusions with reasons given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:10:56 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>No missing data</P>
<P>Quote: "All patients complied with and completed the treatment protocol"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:11:37 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>3 probiotic treatment patients dropped out because of lack of response</P>
<P>Quote: "When data at week 12 were missing because of withdrawals, the last observation was carried forward"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-08 14:11:40 -0500" MODIFIED_BY="John K MacDonald" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:04:41 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>All primary outcomes were reported. Time to clinical remission was not directly reported in text, but it was interpretable from one of their published figures (Figure 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:38 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>The primary outcome of clinical remission was reported</P>
<P>Histopathological changes were also described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:06:00 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:40 -0500" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Outcomes were not pre-specified in the methods section of the manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:43 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:07:42 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:47 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:09:03 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:09:35 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:10:20 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>All primary outcomes were reported. Most secondary outcomes were reported with exception of histological outcomes</P>
<P>Safety and adverse-effect data was also presented, but not described as part of methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:10:59 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:11:40 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>All outcome reported. One <I>post hoc</I> analysis noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-11-08 14:11:41 -0500" MODIFIED_BY="John K MacDonald" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:04:43 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Baert-2002">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:38 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2003">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:06:01 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Bonderup-2009">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:06:41 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:43 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:07:42 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Madisch-2007">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:47 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2002">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:09:03 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2008">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:09:35 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2014">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:50:48 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munch-2016">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:11:00 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Munck-2003">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:11:41 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Wildt-2006">
<DESCRIPTION>
<P>Study appeared to be free of other forms of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-11-08 12:53:15 -0500" MODIFIED_BY="John K MacDonald">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-11-08 12:51:29 -0500" MODIFIED_BY="John K MacDonald" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-11-08 12:51:18 -0500" MODIFIED_BY="John K MacDonald">Bismuth subsalicylate versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Bismuth subsalicylate versus placebo</B> <B>for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Bismuth subsalicylate<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Bismuth subsalicylate</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 10.80<BR/>(0.75 to 155.93)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>9<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Histological response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 10.80<BR/>(0.75 to 155.93)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>9<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data (4 events).<BR/>
<SUP>3</SUP> Downgraded one level due to unclear risk of bias for random sequence generation and allocation concealment.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-11-08 12:51:52 -0500" MODIFIED_BY="John K MacDonald" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-11-08 12:51:42 -0500" MODIFIED_BY="John K MacDonald">
<I>Boswellia serrata</I> extract versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>Boswellia serrata</B>
</I>
<B> extract versus placebo for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>
<I>Boswellia serrata</I> extract<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with <I>Boswellia serrata</I> extract</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>267 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>437 per 1000<BR/>(160 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.64<BR/>(0.60 to 4.49)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>67 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>125 per 1000<BR/>(13 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.88<BR/>(0.19 to 18.60)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 2.82<BR/>(0.12 to 64.39)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study. <BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data (11 events).<BR/>
<SUP>3</SUP> Downgraded two levels due to very sparse data and wide confidence interval (3 events).<BR/>
<SUP>4</SUP> Study had very few events. Downgraded two levels due to very sparse data and wide confidence interval (1 event).<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-11-08 12:51:58 -0500" MODIFIED_BY="John K MacDonald" NO="3" READONLY="YES">
<TITLE MODIFIED="2017-03-08 14:27:23 -0500" MODIFIED_BY="John K MacDonald">Budesonide versus mesalazine for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Budesonide versus mesalazine</B> <B>for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Budesonide<BR/>
<B>Comparison: </B>Mesalazine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with mesalazine</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Budesonide</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>440 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>801 per 1000<BR/>(497 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.82<BR/>(1.13 to 2.93)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological response</P>
</TD>
<TD>
<P>440 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>867 per 1000<BR/>(546 to 1000)</P>
</TD>
<TD>
<P>RR 1.97<BR/>(1.24 to 3.13)</P>
</TD>
<TD>
<P>55<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>680 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>469 per 1000<BR/>(292 to 748)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.69<BR/>(0.43 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>160 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000<BR/>(2 to 264)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.09<BR/>(0.01 to 1.65)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Serious adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>120 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000<BR/>(1 to 265)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.12<BR/>(0.01 to 2.21)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data (35 events).<BR/>
<SUP>3</SUP> Downgraded two levels due to very sparse data (37 events).<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data (31 events).<BR/>
<SUP>5</SUP> Downgraded two levels due to very sparse data and wide confidence interval (4 events).<BR/>
<SUP>6</SUP> Downgraded two levels due to very sparse data and wide confidence intervals (3 events).<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2017-11-08 12:52:22 -0500" MODIFIED_BY="John K MacDonald" NO="4" READONLY="YES">
<TITLE MODIFIED="2017-11-08 12:52:13 -0500" MODIFIED_BY="John K MacDonald">Mesalamine versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mesalamine versus placebo for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Mesalamine<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Mesalamine</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>595 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>440 per 1000<BR/>(262 to 737)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.74<BR/>(0.44 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>62<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological response</P>
</TD>
<TD>
<P>514 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>442 per 1000<BR/>(257 to 755)</P>
</TD>
<TD>
<P>RR 0.86<BR/>(0.50 to 1.47)</P>
</TD>
<TD>
<P>62<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>541 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>681 per 1000<BR/>(454 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.26<BR/>(0.84 to 1.88)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>62<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>27 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>160 per 1000<BR/>(19 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 5.92<BR/>(0.70 to 49.90)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>62<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Serious adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>27 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>120 per 1000<BR/>(13 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 4.44<BR/>(0.49 to 40.29)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>62<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data (33 events).<BR/>
<SUP>3</SUP> Downgraded two levels due to very sparse data (30 events).<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data (37 events).<BR/>
<SUP>5</SUP> Downgraded two levels due to very sparse data and wide confidence interval (5 events).<BR/>
<SUP>6</SUP> Downgraded two levels due to very sparse data and wide confidence interval (4 events).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2017-11-08 12:52:23 -0500" MODIFIED_BY="John K MacDonald" NO="5" READONLY="YES">
<TITLE MODIFIED="2017-03-09 11:35:45 -0500" MODIFIED_BY="John K MacDonald">Mesalazine versus mesalazine + cholestyramine for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mesalazine vs. mesalazine + cholestyramine</B> <B>for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Mesalazine<BR/>
<B>Comparison: </B>Mesalazine + cholestyramine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with mesalazine + cholestyramine</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Mesalazine</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>167 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>123 per 1000<BR/>(83 to 180)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.74<BR/>(0.50 to 1.08)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>23<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.22<BR/>(0.01 to 4.07)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>23<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded one level due to high risk of bias for blinding.<BR/>
<SUP>3</SUP> Downgraded two levels due to very sparse data (20 events).<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data and wide confidence interval (2 events).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2017-11-08 12:52:27 -0500" MODIFIED_BY="John K MacDonald" NO="6" READONLY="YES">
<TITLE MODIFIED="2017-03-09 13:52:16 -0500" MODIFIED_BY="John K MacDonald">Prednisolone versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Prednisolone versus placebo</B> <B>for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Prednisolone<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Prednisolone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 4.89<BR/>(0.35 to 68.83)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data (5 events).<BR/>
<SUP>3</SUP> Downgraded one level due to unclear risk of bias for random sequence generation and allocation concealment.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2017-11-08 12:52:33 -0500" MODIFIED_BY="John K MacDonald" NO="7" READONLY="YES">
<TITLE MODIFIED="2017-03-09 13:02:27 -0500" MODIFIED_BY="John K MacDonald">Probiotics versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Probiotics versus placebo</B> <B>for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatients<BR/>
<B>Intervention: </B>Probiotics<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Probiotics</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>125 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>286 per 1000<BR/>(40 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 2.29<BR/>(0.32 to 16.13)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>29<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>500 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>285 per 1000<BR/>(110 to 750)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.57<BR/>(0.22 to 1.50)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>29<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of the included study.<BR/>
<SUP>2</SUP> Downgraded two levels due to very sparse data and wide confidence interval (7 events).<BR/>
<SUP>3</SUP> Downgraded one level due to unclear risk of bias for allocation concealment.<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data and wide confidence interval (10 events).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2017-11-08 12:53:15 -0500" MODIFIED_BY="John K MacDonald" NO="8" READONLY="YES">
<TITLE MODIFIED="2017-11-08 12:52:45 -0500" MODIFIED_BY="John K MacDonald">Budesonide versus placebo for treating collagenous colitis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Budesonide versus placebo for treating collagenous colitis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Patients with collagenous colitis<BR/>
<B>Setting: </B>Outpatient<BR/>
<B>Intervention: </B>Budesonide<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Budesonide</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
<P>sensitivity analysis excluding Miehlke</P>
<P>2014</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>170 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>722 per 1000<BR/>(388 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 4.56</P>
<P>(2.43 to 8.55)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>94<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological response</P>
<P>sensitivity analysis excluding Miehlke</P>
<P>2014</P>
</TD>
<TD>
<P>170 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>706 per 1000<BR/>(383 to 1000)</P>
</TD>
<TD>
<P>RR 4.15</P>
<P>(2.25 to 7.66)</P>
</TD>
<TD>
<P>94<BR/>(3 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Maintenance of clinical response</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>205 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>675 per 1000<BR/>(436 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 3.30<BR/>(2.13 to 5.09)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>172<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance of histological response</P>
</TD>
<TD>
<P>150 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>476 per 1000<BR/>(216 to 1000)</P>
</TD>
<TD>
<P>RR 3.17<BR/>(1.44 to 6.95)</P>
</TD>
<TD>
<P>80<BR/>(2 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>7,8</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>420 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>496 per 1000<BR/>(386 to 634)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.18<BR/>(0.92 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>290<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>low</B>
<SUP>6,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>73 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>71 per 1000<BR/>(31to 158)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.97<BR/>(0.43 to 2.17)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>290<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>6,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Serious adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>11 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>12 per 1000<BR/>(2 to 88)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.11<BR/>(0.15 to 8.01)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>175<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>11,12</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk comes from control arm of meta-analysis, based on included trials.<BR/>
<SUP>2</SUP> Downgraded one level due to sparse data (46 events).<BR/>
<SUP>3</SUP> Downgraded one level due unclear risk of bias for random sequence generation and blinding in one study and random sequence generation and incomplete outcome data in another study in the pooled analysis.<BR/>
<SUP>4</SUP> Downgraded one level due to sparse data (42 events).<BR/>
<SUP>5</SUP> Downgraded one level due to sparse data (75 events).<BR/>
<SUP>6</SUP> Downgraded one level due unclear risk of bias for sequence generation in one study and allocation concealment in two studies in the pooled analysis.<BR/>
<SUP>7</SUP> Downgraded two levels due to very sparse data (25 events).<BR/>
<SUP>8</SUP> Downgraded one level due unclear risk of bias for random sequence generation and allocation concealment in one study in the pooled analysis.<BR/>
<SUP>9</SUP> Downgraded one level due to sparse data (131 events).<BR/>
<SUP>10</SUP> Downgraded two levels due to very sparse data (21 events).<BR/>
<SUP>11</SUP> Downgraded two levels due to very sparse data and wide confidence interval (2 events).<BR/>
<SUP>12</SUP> Downgraded one level due unclear risk of bias for sequence generation in two studies, blinding in one study and allocation concealment in one study in the pooled analysis.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Unblinded studies of therapies for collagenous colitis</TITLE>
<TABLE COLS="2" ROWS="22">
<TR>
<TH>
<P>Therapy</P>
</TH>
<TH>
<P>References</P>
</TH>
</TR>
<TR>
<TD>
<P>5-ASA compounds</P>
</TD>
<TD>
<P>Weidner 1984, Farah 1985, Giardiello 1987, Wang 1987, Jessurun 1987, Eckstein 1988, Mason 1988, Rokkas 1988, O'Mahony 1990, Gubbins 1991, Giardiello 1991, Carpenter 1992, Fasoli 1994, Katanuma 1995, Bohr 1996, Goff 1997, Mullhaupt 1998, Wang 1999, Bonner 2000, Fielder 2001, Pardi 2001, Kimble 2001, Bozdech 2001, Abdo 2002, Fernandez 2003, Honkoop 2003, Randall 2003, Buchman 2004, Mowat 2005, Fekih 2006, Roe 2006, Madisch 2006, Narvaez 2006, de la Iglesia 2007, Ekiz 2007, Freeman 2007, Koch 2007, Halsey 2007, Rubio-Tapia 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Antibiotics</P>
</TD>
<TD>
<P>Mogensen 1984, Wang 1987, Puri 1994, Pimental 1995, Bohr 1996, Mullhaupt 1998, Swensson 1999, Honkoop 2001, Madisch 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Antihistamine</P>
</TD>
<TD>
<P>Benchimol 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Azathioprine/6-mercaptopurine</P>
</TD>
<TD>
<P>Goff 1997, Pardi 2001, Roe 2006, Wickbom 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Bismuth subsalicylate</P>
</TD>
<TD>
<P>Girard 1987, Fine 1998, Bohr 1999, Bozdech 2001, Buchman 2004, Madisch 2006, Chande 2007, Rubio-Tapia 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Budesonide</P>
</TD>
<TD>
<P>Van Gossum 1998, Delarive 1998, Lanyi 1999, Tromm 1999, Bohr 1999, Mueller-Wittlic 2000, Bajor 2003, Fernandez 2003, Honkoop 2003, Buchman 2004, Hawkins 2004, Barta 2005, Bajor 2006, Roe 2006, Wickbom 2006, Freeman 2006, Hilmer 2006, Chopra 2006, Kiesslich 2006, de la Iglesia 2007, Freeman 2007, Brar 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Cholestyramine/colestipol</P>
</TD>
<TD>
<P>Andersen 1993, Bohr 1996, Ung 2000, Fernandez 2003, Baert 2004, Mahmoud 2005, Hilmer 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Cyclosporine</P>
</TD>
<TD>
<P>Eijsbouts 1995, Roe 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Dietary modification</P>
</TD>
<TD>
<P>Fekih 2006</P>
</TD>
</TR>
<TR>
<TD>
<P>Elemental diet</P>
</TD>
<TD>
<P>Teahon 1994</P>
</TD>
</TR>
<TR>
<TD>
<P>Ketotifen</P>
</TD>
<TD>
<P>Marshall 1998, Benchimol 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Methotrexate</P>
</TD>
<TD>
<P>Bhullar 1996, Hillman 2001, Riddell 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Octreotide</P>
</TD>
<TD>
<P>Fisher 1996, Goff 1997</P>
</TD>
</TR>
<TR>
<TD>
<P>Pentoxifylline</P>
</TD>
<TD>
<P>Peterson 1996, Williams 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>Probiotics</P>
</TD>
<TD>
<P>Tromm 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>Steroids, intravenous</P>
</TD>
<TD>
<P>Pardi 2001, Buchman 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>Steroids, oral</P>
</TD>
<TD>
<P>Palmer 1986, Hamilton 1986, Giardiello 1987, Wang 1987, Jessurun 1987, O'Mahony 1990, Sloth 1991, Giardiello 1991, Carpenter 1992, Fasoli 1994, Pimental 1995, Katanuma 1995, Bohr 1996, Goff 1997, Duncan 1997, Wang 1999, Castellano 1999, Swensson 1999, Bonner 2000, Fielder 2001, Persoz 2001, Honkoop 2001, Abdo 2002, Fernandez 2003, Honkoop 2003, Buchman 2004, Mowat 2005, O'Beirne 2005, Taha 2006, Madisch 2006, Narvaez 2006, Rubio-Tapia 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Steroids, topical</P>
</TD>
<TD>
<P>Wang 1987, Mason 1988</P>
</TD>
</TR>
<TR>
<TD>
<P>Surgery</P>
</TD>
<TD>
<P>Jarnerot 1995, Alikhan 1997, Munch 2005, Shen 2006, Davis 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Symptomatic therapy: antidiarrheal agents, bulking agents, spasmolytics</P>
</TD>
<TD>
<P>Bamford 1982, Eaves 1983, Giardiello 1987, Wang 1987, Gubbins 1991, Pimental 1995, Katanuma 1995, Bohr 1996, Goff 1997, Mullhaupt 1998, Wang 1999, Fielder 2001, Abdo 2002, Honkoop 2003, Mowat 2005, Smith 2005, Fekih 2006, Hilmer 2006, Madisch 2006, Ekiz 2007, Khawaja 2007, Halsey 2007</P>
</TD>
</TR>
<TR>
<TD>
<P>Verapamil</P>
</TD>
<TD>
<P>Scheidler 2001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-08 12:54:26 -0500" MODIFIED_BY="John K MacDonald">
<COMPARISON ID="CMP-001" MODIFIED="2017-03-09 08:05:54 -0500" MODIFIED_BY="John K MacDonald" NO="1">
<NAME>Bismuth subsalicylate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-07 13:00:32 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="155.92656021636896" CI_START="0.7480444629711984" EFFECT_SIZE="10.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192920098337853" LOG_CI_START="-0.1260725873639538" LOG_EFFECT_SIZE="1.0334237554869496" ORDER="1481" O_E="0.0" SE="1.3621877827801698" STUDY_ID="STD-Fine-1999" TOTAL_1="4" TOTAL_2="5" VAR="1.8555555555555554" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-07 13:00:41 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="155.92656021636896" CI_START="0.7480444629711984" EFFECT_SIZE="10.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192920098337853" LOG_CI_START="-0.1260725873639538" LOG_EFFECT_SIZE="1.0334237554869496" ORDER="1482" O_E="0.0" SE="1.3621877827801698" STUDY_ID="STD-Fine-1999" TOTAL_1="4" TOTAL_2="5" VAR="1.8555555555555554" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 08:05:12 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:03:46 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="122" O_E="0.0" SE="0.0" STUDY_ID="STD-Fine-1999" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 08:05:33 -0500" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:04:01 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="123" O_E="0.0" SE="0.0" STUDY_ID="STD-Fine-1999" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 08:05:54 -0500" MODIFIED_BY="John K MacDonald" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:04:10 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="124" O_E="0.0" SE="0.0" STUDY_ID="STD-Fine-1999" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-11-06 13:56:16 -0500" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Boswellia serrata extract versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-08 12:36:33 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="158.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Boswellia serrata</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours boswellia</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.4885713752665755" CI_START="0.5996675034414807" EFFECT_SIZE="1.640625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6521081355321539" LOG_CI_START="-0.22208948536005196" LOG_EFFECT_SIZE="0.2150093250860509" ORDER="1494" O_E="0.0" SE="0.5135080098600957" STUDY_ID="STD-Madisch-2007" TOTAL_1="16" TOTAL_2="15" VAR="0.2636904761904762" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 09:32:06 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Boswellia serrata</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours boswellia</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.60416152208956" CI_START="0.18896981709311333" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2696101014182621" LOG_CI_START="-0.7236075572907867" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2012-08-07 11:10:27 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="125" O_E="0.0" SE="1.1708259193122321" STUDY_ID="STD-Madisch-2007" TOTAL_1="16" TOTAL_2="15" VAR="1.3708333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-06 13:56:16 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Boswellia serrata</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours boswellia</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.38881850957007" CI_START="0.12381526053184887" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8088104561608964" LOG_CI_START="-0.9072258241662695" LOG_EFFECT_SIZE="0.45079231599731334" MODIFIED="2012-08-07 11:10:46 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="126" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Madisch-2007" TOTAL_1="16" TOTAL_2="15" VAR="2.545343137254902" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-11-07 11:44:11 -0500" MODIFIED_BY="John K MacDonald" NO="3">
<NAME>Budesonide versus mesalazine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-08 14:30:01 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9296637687774227" CI_START="1.1283837958464698" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.4668177801685523" LOG_CI_START="0.05245684084296004" LOG_EFFECT_SIZE="0.2596373105057561" MODIFIED="2012-08-07 10:12:46 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="97" O_E="0.0" SE="0.24339766687958256" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="25" VAR="0.05924242424242424" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-08 14:30:09 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.132546538989296" CI_START="1.2385150880105353" EFFECT_SIZE="1.9696969696969697" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="11" LOG_CI_END="0.49589753185329244" LOG_CI_START="0.09290130167664383" LOG_EFFECT_SIZE="0.2943994167649681" MODIFIED="2012-08-07 10:12:57 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="98" O_E="0.0" SE="0.2367219804692755" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="25" VAR="0.05603729603729605" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 09:53:54 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0954046772047012" CI_START="0.4299531603319975" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.039574590965466644" LOG_CI_START="-0.3665788544607881" LOG_EFFECT_SIZE="-0.16350213174766073" MODIFIED="2012-08-07 11:50:19 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="138" O_E="0.0" SE="0.23857654433536166" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="25" VAR="0.05691876750700279" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 09:54:36 -0500" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6516258759359805" CI_START="0.005258072997187147" EFFECT_SIZE="0.0931899641577061" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.21791167832483643" LOG_CI_START="-2.2791733889303956" LOG_EFFECT_SIZE="-1.0306308553027796" MODIFIED="2012-08-07 11:50:40 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="139" O_E="0.0" SE="1.4668001292761583" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="25" VAR="2.151502619244555" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 09:55:17 -0500" MODIFIED_BY="John K MacDonald" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.214852457920999" CI_START="0.006481603004992184" EFFECT_SIZE="0.11981566820276497" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.345344801057986" LOG_CI_START="-2.1883175728134088" LOG_EFFECT_SIZE="-0.9214863858777116" MODIFIED="2012-08-07 11:51:01 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="140" O_E="0.0" SE="1.4882858202430802" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="25" VAR="2.2149946827366183" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-11-08 12:53:37 -0500" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Mesalamine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 07:52:29 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Mesalamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2398489996026523" CI_START="0.4416666869719581" EFFECT_SIZE="0.74" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.09336879594242783" LOG_CI_START="-0.35490535648047544" LOG_EFFECT_SIZE="-0.13076828026902382" MODIFIED="2012-08-07 09:55:01 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="95" O_E="0.0" SE="0.2633184561260553" STUDY_ID="STD-Miehlke-2014" TOTAL_1="25" TOTAL_2="37" VAR="0.06933660933660932" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 07:52:37 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Mesalamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mesalamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4735080263425464" CI_START="0.49825204900589126" EFFECT_SIZE="0.8568421052631578" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.16835250583696804" LOG_CI_START="-0.3025509066362611" LOG_EFFECT_SIZE="-0.06709920039964655" MODIFIED="2012-08-07 09:55:36 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="96" O_E="0.0" SE="0.27661099549626056" STUDY_ID="STD-Miehlke-2014" TOTAL_1="25" TOTAL_2="37" VAR="0.0765136428294323" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:09:07 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Mesalamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8780274105657848" CI_START="0.8426735366568627" EFFECT_SIZE="1.258" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.27370192667907617" LOG_CI_START="-0.07434064446057596" LOG_EFFECT_SIZE="0.09968064110925012" MODIFIED="2012-08-07 11:57:38 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="141" O_E="0.0" SE="0.2044419291259444" STUDY_ID="STD-Miehlke-2014" TOTAL_1="25" TOTAL_2="37" VAR="0.04179650238473767" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:10:55 -0500" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Mesalamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="49.90307741293012" CI_START="0.7022893540212675" EFFECT_SIZE="5.92" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6981273284338834" LOG_CI_START="-0.15348391498804395" LOG_EFFECT_SIZE="0.7723217067229198" MODIFIED="2012-08-07 11:58:22 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="142" O_E="0.0" SE="1.0876456100095164" STUDY_ID="STD-Miehlke-2014" TOTAL_1="25" TOTAL_2="37" VAR="1.182972972972973" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:11:15 -0500" MODIFIED_BY="John K MacDonald" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Mesalamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="40.29418887039085" CI_START="0.4892417629601683" EFFECT_SIZE="4.44" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.605242417766468" LOG_CI_START="-0.310476477537228" LOG_EFFECT_SIZE="0.6473829701146199" MODIFIED="2012-08-07 11:58:43 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="143" O_E="0.0" SE="1.125302762062862" STUDY_ID="STD-Miehlke-2014" TOTAL_1="25" TOTAL_2="37" VAR="1.2663063063063063" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-11-07 11:44:14 -0500" MODIFIED_BY="John K MacDonald" NO="5">
<NAME>Mesalazine vs. mesalazine + cholestyramine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 07:53:14 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>5-ASA + cholest</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA+chole.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-ASA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0761306023032489" CI_START="0.504286168069453" EFFECT_SIZE="0.7366666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.03186498175568913" LOG_CI_START="-0.2973229438247925" LOG_EFFECT_SIZE="-0.13272898103455172" ORDER="1496" O_E="0.0" SE="0.19336661699248694" STUDY_ID="STD-Calabrese-2007" TOTAL_1="11" TOTAL_2="12" VAR="0.03739064856711914" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:16:11 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>5-ASA + cholest</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-ASA+chole.</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.070811587660094" CI_START="0.011531961977004238" EFFECT_SIZE="0.21666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6096810020764933" LOG_CI_START="-1.938096798230107" LOG_EFFECT_SIZE="-0.6642078980768068" MODIFIED="2015-08-20 10:51:28 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1496" O_E="0.0" SE="1.4965772916036075" STUDY_ID="STD-Calabrese-2007" TOTAL_1="11" TOTAL_2="12" VAR="2.2397435897435893" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-11-07 12:35:33 -0500" MODIFIED_BY="John K MacDonald" NO="6">
<NAME>Prednisolone versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 07:54:05 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="3" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prednisolone</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.82827301529929" CI_START="0.34725896090097214" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.8377668727160865" LOG_CI_START="-0.45934653862236113" LOG_EFFECT_SIZE="0.6892101670468626" ORDER="1493" O_E="0.0" SE="1.3493357887149775" STUDY_ID="STD-Munck-2003" TOTAL_1="8" TOTAL_2="3" VAR="1.8207070707070705" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:22:09 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="3" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prednisolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 12:03:01 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="144" O_E="0.0" SE="0.0" STUDY_ID="STD-Munck-2003" TOTAL_1="8" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2017-11-07 12:35:33 -0500" MODIFIED_BY="John K MacDonald" NO="7">
<NAME>Probiotics versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 07:53:38 -0500" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="138.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours probiotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.131931410783544" CI_START="0.32386015430402876" EFFECT_SIZE="2.2857142857142856" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2076863668204836" LOG_CI_START="-0.4896424815371478" LOG_EFFECT_SIZE="0.3590219426416679" ORDER="1495" O_E="0.0" SE="0.9970193674385764" STUDY_ID="STD-Wildt-2006" TOTAL_1="21" TOTAL_2="8" VAR="0.9940476190476191" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:20:06 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5047540601463716" CI_START="0.21699932294127544" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.1774655238172535" LOG_CI_START="-0.6635416211898425" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-08-20 10:36:51 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="145" O_E="0.0" SE="0.49401176002967684" STUDY_ID="STD-Wildt-2006" TOTAL_1="21" TOTAL_2="8" VAR="0.244047619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-03-09 10:20:38 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Probiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours probiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-20 10:32:26 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="145" O_E="0.0" SE="0.0" STUDY_ID="STD-Wildt-2006" TOTAL_1="21" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2017-11-08 12:54:26 -0500" MODIFIED_BY="John K MacDonald" NO="8">
<NAME>Budesonide versus placebo</NAME>
<DICH_OUTCOME CHI2="15.654453806782797" CI_END="7.748978710986289" CI_START="1.1444539035364147" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9779773226485178" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="30" I2="80.83612474106152" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.8892444677436855" LOG_CI_START="0.05859830479305387" LOG_EFFECT_SIZE="0.47392138626836966" METHOD="MH" MODIFIED="2017-02-07 10:15:51 -0500" MODIFIED_BY="Tran M Nguyen" NO="1" P_CHI2="0.001334780304516614" P_Q="1.0" P_Z="0.02531923000256917" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7370103941390306" TOTALS="YES" TOTAL_1="77" TOTAL_2="84" WEIGHT="100.00000000000001" Z="2.2364970549909255">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.26892856523757" CI_START="1.023446973884002" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9174492401027019" LOG_CI_START="0.010065346220659995" LOG_EFFECT_SIZE="0.46375729316168096" MODIFIED="2017-02-07 10:15:51 -0500" MODIFIED_BY="Tran M Nguyen" NOTES="&lt;p&gt;&lt;span modified=&quot;2017-02-07 10:11:00 -0500&quot; class=&quot;inserted&quot; modified_by=&quot;Tran M Nguyen&quot;&gt;Munch 2016 isn't included in the clinical response because the study started with an 8 week open label induction phase study where everyone received budesonide&lt;/span&gt;&lt;span modified=&quot;2017-02-07 10:12:00 -0500&quot; class=&quot;inserted&quot; modified_by=&quot;Tran M Nguyen&quot;&gt; (therefore, there was no control group). &lt;/span&gt;&lt;span modified=&quot;2017-02-07 10:15:00 -0500&quot; class=&quot;inserted&quot; modified_by=&quot;Tran M Nguyen&quot;&gt;Afterwards the 92/110 patients who entered clinical remission were randomised to either budesonide or placebo. &lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-02-07 10:15:51 -0500" NOTES_MODIFIED_BY="Tran M Nguyen" ORDER="1483" O_E="0.0" SE="0.5330017908890261" STUDY_ID="STD-Baert-2002" TOTAL_1="11" TOTAL_2="12" VAR="0.2840909090909091" WEIGHT="23.31516536361777"/>
<DICH_DATA CI_END="12.583031067983816" CI_START="1.4018879795094135" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.099785268894548" LOG_CI_START="0.1467133119012532" LOG_EFFECT_SIZE="0.6232492903979004" ORDER="1484" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Bonderup-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="22.664183969649727"/>
<DICH_DATA CI_END="18.917685805408293" CI_START="2.17211490178603" EFFECT_SIZE="6.410256410256411" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.2768680082067911" LOG_CI_START="0.33688279508428576" LOG_EFFECT_SIZE="0.8068754016455384" MODIFIED="2015-08-20 13:34:21 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1485" O_E="0.0" SE="0.5521519671900073" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="0.3048717948717949" WEIGHT="22.850132182808903"/>
<DICH_DATA CI_END="1.8540221349455899" CI_START="0.9763896017009651" EFFECT_SIZE="1.3454545454545455" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.26811491482861954" LOG_CI_START="-0.01037685435515488" LOG_EFFECT_SIZE="0.12886903023673235" MODIFIED="2015-08-20 13:52:48 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="34" O_E="0.0" SE="0.16358744377503967" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="37" VAR="0.026760851760851766" WEIGHT="31.17051848392362"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1140454692451753" CI_END="8.553131124250434" CI_START="2.4339211237096188" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.562635917665504" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.9321251300557674" LOG_CI_START="0.38630649990361043" LOG_EFFECT_SIZE="0.659215814979689" METHOD="MH" MODIFIED="2017-11-08 12:54:12 -0500" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.5729123792799169" P_Q="1.0" P_Z="2.197937968231716E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="4.7343171670019055">
<NAME>Clinical response sensitivity analysis excluding Miehlke 2014</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.26892856523757" CI_START="1.023446973884002" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9174492401027019" LOG_CI_START="0.010065346220659995" LOG_EFFECT_SIZE="0.46375729316168096" MODIFIED="2015-08-20 14:42:13 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1483" O_E="0.0" SE="0.5330017908890261" STUDY_ID="STD-Baert-2002" TOTAL_1="11" TOTAL_2="12" VAR="0.2840909090909091" WEIGHT="34.04642694583523"/>
<DICH_DATA CI_END="12.583031067983816" CI_START="1.4018879795094135" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.099785268894548" LOG_CI_START="0.1467133119012532" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2015-08-20 14:42:13 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1484" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Bonderup-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="29.661659839174632"/>
<DICH_DATA CI_END="18.917685805408293" CI_START="2.17211490178603" EFFECT_SIZE="6.410256410256411" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.2768680082067911" LOG_CI_START="0.33688279508428576" LOG_EFFECT_SIZE="0.8068754016455384" MODIFIED="2015-08-20 14:42:13 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1485" O_E="0.0" SE="0.5521519671900073" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="0.3048717948717949" WEIGHT="36.29191321499014"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.080137396900316" CI_END="5.244857251801925" CI_START="1.3726628672348382" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.683173642069381" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="27" I2="62.871918475657935" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.7197336725870853" LOG_CI_START="0.13756388546820653" LOG_EFFECT_SIZE="0.428648779027646" METHOD="MH" MODIFIED="2017-11-06 13:58:15 -0500" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.04438434949284964" P_Q="1.0" P_Z="0.0038989470814518343" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2672359671210532" TOTALS="YES" TOTAL_1="77" TOTAL_2="84" WEIGHT="100.00000000000001" Z="2.8862238731729266">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.202712229538406" CI_START="1.1991555070867992" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.7925816328459929" LOG_CI_START="0.07887550627688181" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2015-08-20 10:20:46 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1486" O_E="0.0" SE="0.4192345116490003" STUDY_ID="STD-Baert-2002" TOTAL_1="11" TOTAL_2="12" VAR="0.17575757575757572" WEIGHT="26.398371375366974"/>
<DICH_DATA CI_END="7.193915048670496" CI_START="1.2510573087269479" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8569653050266306" LOG_CI_START="0.09727720441269429" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-20 13:33:13 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1487" O_E="0.0" SE="0.4462445508173731" STUDY_ID="STD-Bonderup-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.19913419913419908" WEIGHT="25.07516326719558"/>
<DICH_DATA CI_END="94.90688556931102" CI_START="1.9093769294445813" EFFECT_SIZE="13.461538461538462" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.9772977219771057" LOG_CI_START="0.2808916707818097" LOG_EFFECT_SIZE="1.1290946963794577" MODIFIED="2015-08-20 13:43:57 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1488" O_E="0.0" SE="0.9964773118175009" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="0.9929670329670328" WEIGHT="9.27970181072588"/>
<DICH_DATA CI_END="2.379700609972733" CI_START="1.1969557925622019" EFFECT_SIZE="1.687719298245614" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.3765223219239248" LOG_CI_START="0.07807811080671827" LOG_EFFECT_SIZE="0.22730021636532155" MODIFIED="2015-08-20 13:52:46 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="99" O_E="0.0" SE="0.1753076069329181" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="37" VAR="0.03073275704854652" WEIGHT="39.24676354671157"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9302030136730286" CI_END="7.661073908735306" CI_START="2.2513825930581044" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.153072169160835" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" I2="31.745343559216845" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.8842896521322712" LOG_CI_START="0.352449303945413" LOG_EFFECT_SIZE="0.6183694780388421" METHOD="MH" MODIFIED="2017-11-08 12:54:26 -0500" MODIFIED_BY="John K MacDonald" NO="4" P_CHI2="0.23105458978922422" P_Q="1.0" P_Z="5.171912340171881E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.00000000000001" Z="4.557690706343859">
<NAME>Histological response sensitivity analysis excluding Miehlke 2014</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.202712229538406" CI_START="1.1991555070867992" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.7925816328459929" LOG_CI_START="0.07887550627688181" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2015-08-20 14:46:47 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1486" O_E="0.0" SE="0.4192345116490003" STUDY_ID="STD-Baert-2002" TOTAL_1="11" TOTAL_2="12" VAR="0.17575757575757572" WEIGHT="45.84503805097299"/>
<DICH_DATA CI_END="7.193915048670496" CI_START="1.2510573087269479" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8569653050266306" LOG_CI_START="0.09727720441269429" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-20 14:46:47 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1487" O_E="0.0" SE="0.4462445508173731" STUDY_ID="STD-Bonderup-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.19913419913419908" WEIGHT="41.93779048981052"/>
<DICH_DATA CI_END="94.90688556931102" CI_START="1.9093769294445813" EFFECT_SIZE="13.461538461538462" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.9772977219771057" LOG_CI_START="0.2808916707818097" LOG_EFFECT_SIZE="1.1290946963794577" MODIFIED="2015-08-20 14:46:47 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="1488" O_E="0.0" SE="0.9964773118175009" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="0.9929670329670328" WEIGHT="12.217171459216507"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0959668807351233" CI_END="5.093151086395256" CI_START="2.132424188469032" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2955665024630547" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="18" I2="35.39982573957286" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.7069865595483564" LOG_CI_START="0.3288736001608641" LOG_EFFECT_SIZE="0.5179300798546103" METHOD="MH" MODIFIED="2017-02-03 13:05:10 -0500" MODIFIED_BY="Tran M Nguyen" NO="5" P_CHI2="0.21267651166774704" P_Q="1.0" P_Z="7.898873814045454E-8" Q="0.0" RANDOM="NO" SCALE="38.51" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="88" WEIGHT="100.00000000000001" Z="5.369423490109396">
<NAME>Maintenance of clinical response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.534196748560525" CI_START="1.72208613279662" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.3897718437158204" LOG_CI_START="0.23605486956989086" LOG_EFFECT_SIZE="0.8129133566428556" ORDER="1489" O_E="0.0" SE="0.6776990616044466" STUDY_ID="STD-Bonderup-2009" TOTAL_1="17" TOTAL_2="17" VAR="0.45927601809954743" WEIGHT="11.330049261083746"/>
<DICH_DATA CI_END="3.910950769918246" CI_START="1.1546105450195667" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.5922823491949295" LOG_CI_START="0.06243551957773127" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2008-08-15 12:38:06 -0400" MODIFIED_BY="John K MacDonald" ORDER="1490" O_E="0.0" SE="0.3112346505012485" STUDY_ID="STD-Miehlke-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.09686700767263429" WEIGHT="45.32019704433498"/>
<DICH_DATA CI_END="7.2285195549342465" CI_START="1.8753197001056257" EFFECT_SIZE="3.6818181818181817" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" LOG_CI_END="0.8590493602325278" LOG_CI_START="0.2730753158803592" LOG_EFFECT_SIZE="0.5660623380564435" MODIFIED="2017-01-30 10:42:31 -0500" MODIFIED_BY="Tran M Nguyen" ORDER="60" O_E="0.0" SE="0.3442040542707639" STUDY_ID="STD-Munch-2016" TOTAL_1="44" TOTAL_2="48" VAR="0.11847643097643097" WEIGHT="43.34975369458129"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27484693019168477" CI_END="6.948220534738222" CI_START="1.443215241606544" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1666666666666665" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.8418735943893231" LOG_CI_START="0.1593311067490474" LOG_EFFECT_SIZE="0.5006023505691853" METHOD="MH" MODIFIED="2015-08-20 14:47:00 -0400" MODIFIED_BY="Petrease  H Patton" NO="6" P_CHI2="0.6000988430115033" P_Q="1.0" P_Z="0.004039984332728078" Q="0.0" RANDOM="NO" SCALE="22.22" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.00000000000001" Z="2.8750227142161595">
<NAME>Maintenance of histological response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="38.41737465163205" CI_START="0.6507472263968965" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5845276829289354" LOG_CI_START="-0.18658767425689776" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1492" O_E="0.0" SE="1.0403619279733713" STUDY_ID="STD-Bonderup-2009" TOTAL_1="17" TOTAL_2="17" VAR="1.0823529411764705" WEIGHT="16.666666666666668"/>
<DICH_DATA CI_END="6.497568661490716" CI_START="1.2066051793289234" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8127508774995577" LOG_CI_START="0.08156518518488064" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="1491" O_E="0.0" SE="0.42950209509319165" STUDY_ID="STD-Miehlke-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.18447204968944103" WEIGHT="83.33333333333334"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.563697733136156" CI_END="1.5130052102741431" CI_START="0.9177385272400952" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1783646181821579" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="63" I2="47.115813704767525" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.17984042358790148" LOG_CI_START="-0.037281035957685775" LOG_EFFECT_SIZE="0.07127969381510785" METHOD="MH" MODIFIED="2017-03-09 09:34:13 -0500" MODIFIED_BY="John K MacDonald" NO="7" P_CHI2="0.10893318303132571" P_Q="1.0" P_Z="0.1981329036612337" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="150" WEIGHT="100.0" Z="1.286889218588004">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5257498987609512" CI_START="0.2560216456951584" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.183483349811615" LOG_CI_START="-0.5917233151234645" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2017-03-08 14:05:03 -0500" MODIFIED_BY="John K MacDonald" ORDER="127" O_E="0.0" SE="0.45536023231774486" STUDY_ID="STD-Bonderup-2009" TOTAL_1="17" TOTAL_2="17" VAR="0.20735294117647057" WEIGHT="13.349844191515764"/>
<DICH_DATA CI_END="10.301860647520552" CI_START="0.9971836314618383" EFFECT_SIZE="3.2051282051282053" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0129156709161204" LOG_CI_START="-0.0012248589530059575" LOG_EFFECT_SIZE="0.5058454059815573" MODIFIED="2012-08-07 11:22:31 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="128" O_E="0.0" SE="0.5957111673217105" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="0.35487179487179493" WEIGHT="5.104352190873674"/>
<DICH_DATA CI_END="2.2064984637120384" CI_START="0.4532067510791189" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3437036294031449" LOG_CI_START="-0.34370362940314486" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:22:44 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="129" O_E="0.0" SE="0.4037864265436241" STUDY_ID="STD-Miehlke-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.16304347826086957" WEIGHT="13.349844191515764"/>
<DICH_DATA CI_END="1.401287639533616" CI_START="0.5318996781363988" EFFECT_SIZE="0.8633333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.14652729120317798" LOG_CI_START="-0.2741702724799992" LOG_EFFECT_SIZE="-0.06382149063841064" MODIFIED="2017-03-08 14:05:14 -0500" MODIFIED_BY="John K MacDonald" ORDER="130" O_E="0.0" SE="0.24711983139402444" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="37" VAR="0.06106821106821106" WEIGHT="29.887710876527827"/>
<DICH_DATA CI_END="1.9827295412711912" CI_START="1.0014160523424962" EFFECT_SIZE="1.4090909090909092" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.29726347731964825" LOG_CI_START="6.145487044846536E-4" LOG_EFFECT_SIZE="0.14893901301206647" MODIFIED="2017-03-08 14:05:33 -0500" MODIFIED_BY="John K MacDonald" ORDER="61" O_E="0.0" SE="0.17425304910442638" STUDY_ID="STD-Munch-2016" TOTAL_1="44" TOTAL_2="48" VAR="0.03036412512218963" WEIGHT="38.308248549566976"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1974947321617857" CI_END="2.1699057626678058" CI_START="0.4299222265366768" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9658626801263773" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.3364408731839871" LOG_CI_START="-0.3666101017248058" LOG_EFFECT_SIZE="-0.015084614270409363" METHOD="MH" MODIFIED="2017-03-09 08:30:15 -0500" MODIFIED_BY="John K MacDonald" NO="8" P_CHI2="0.6994879898312967" P_Q="1.0" P_Z="0.9329723848452671" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="150" WEIGHT="99.99999999999999" Z="0.08410570995799223">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.717663958438468" CI_START="0.06794556546636217" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1678388826597432" LOG_CI_START="-1.1678388826597432" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-20 11:43:27 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="131" O_E="0.0" SE="1.3719886811400708" STUDY_ID="STD-Bonderup-2009" TOTAL_1="17" TOTAL_2="17" VAR="1.8823529411764706" WEIGHT="9.039069122293288"/>
<DICH_DATA CI_END="19.900760915747448" CI_START="0.1858333391234606" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2988696821982768" LOG_CI_START="-0.7308763694678753" LOG_EFFECT_SIZE="0.28399665636520083" MODIFIED="2012-08-07 11:23:53 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="132" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-Miehlke-2002" TOTAL_1="26" TOTAL_2="25" VAR="1.4215384615384614" WEIGHT="9.216305771750019"/>
<DICH_DATA CI_END="26.755512560869924" CI_START="0.33637927808426854" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4274132752588893" LOG_CI_START="-0.47317076581956424" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-08-07 11:24:04 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="133" O_E="0.0" SE="1.1164124737722179" STUDY_ID="STD-Miehlke-2008" TOTAL_1="23" TOTAL_2="23" VAR="1.2463768115942029" WEIGHT="9.039069122293288"/>
<DICH_DATA CI_END="9.681804404318333" CI_START="0.017244277042976947" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9859563046028171" LOG_CI_START="-1.7633550084770668" LOG_EFFECT_SIZE="-0.38869935193712496" MODIFIED="2012-08-07 11:24:30 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="134" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="37" VAR="2.6080928126768534" WEIGHT="12.183093164830083"/>
<DICH_DATA CI_END="1.9852802069604325" CI_START="0.1957398321959825" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2978218127355753" LOG_CI_START="-0.7083207883293646" LOG_EFFECT_SIZE="-0.20524948779689467" MODIFIED="2017-01-30 10:38:26 -0500" MODIFIED_BY="Tran M Nguyen" ORDER="59" O_E="0.0" SE="0.5910131443517452" STUDY_ID="STD-Munch-2016" TOTAL_1="44" TOTAL_2="48" VAR="0.3492965367965368" WEIGHT="60.522462818833326"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.769762698317568" CI_END="8.007909270545227" CI_START="0.1538060313519567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1098039215686273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.9035191439511857" LOG_CI_START="-0.8130266337705158" LOG_EFFECT_SIZE="0.045246255090335" METHOD="MH" MODIFIED="2017-03-09 09:35:47 -0500" MODIFIED_BY="John K MacDonald" NO="9" P_CHI2="0.3802905129192867" P_Q="1.0" P_Z="0.9177050493222523" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="91" WEIGHT="100.0" Z="0.10332498155693963">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:25:03 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Baert-2002" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.84318997239909" CI_START="0.1307318850798215" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-20 11:49:18 -0400" MODIFIED_BY="Petrease  H Patton" ORDER="154" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Bonderup-2009" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="27.058823529411764"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-07 11:25:11 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Miehlke-2008" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.681804404318333" CI_START="0.017244277042976947" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9859563046028171" LOG_CI_START="-1.7633550084770668" LOG_EFFECT_SIZE="-0.38869935193712496" MODIFIED="2012-08-07 11:25:22 -0400" MODIFIED_BY="David J. Tsoulis" ORDER="136" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Miehlke-2014" TOTAL_1="30" TOTAL_2="37" VAR="2.6080928126768534" WEIGHT="72.94117647058823"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-11-08 14:11:42 -0500" MODIFIED_BY="John K MacDonald">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-08 12:56:42 -0500" MODIFIED_BY="John K MacDonald" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAABBdElEQVR42u2dDYRWXdu/H5IkSSQZ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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-08 14:11:42 -0500" MODIFIED_BY="John K MacDonald" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASYAAAKCCAIAAADzw+PoAAAdQUlEQVR42u3dsW4UW7bG8ZaQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-11-08 12:57:20 -0500" MODIFIED_BY="John K MacDonald">
<APPENDIX ID="APP-01" MODIFIED="2017-11-08 12:57:20 -0500" MODIFIED_BY="John K MacDonald" NO="1">
<TITLE MODIFIED="2017-11-08 12:57:20 -0500" MODIFIED_BY="John K MacDonald">Electronic Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-30 16:09:12 -0400" MODIFIED_BY="Tran M Nguyen">
<P>
<B>MEDLINE Search Strategy:</B>
</P>
<P>1. random$.tw.</P>
<P>2. factorial$.tw.</P>
<P>3. (crossover$ or cross over$ or cross-over$).tw.</P>
<P>4. placebo$.tw.</P>
<P>5. single blind.mp.</P>
<P>6. double blind.mp.</P>
<P>7. triple blind.mp.</P>
<P>8. (singl$ adj blind$).tw.</P>
<P>9. (double$ adj blind$).tw.</P>
<P>10. (tripl$ adj blind$).tw.</P>
<P>11. assign$.tw.</P>
<P>12. allocat$.tw.</P>
<P>13. crossover procedure/</P>
<P>14. double blind procedure/</P>
<P>15. single blind procedure/</P>
<P>16. triple blind procedure/</P>
<P>17. randomized controlled trial/</P>
<P>18. or/1-17</P>
<P>19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)</P>
<P>20. 18 not 19</P>
<P>21. lymphocytic colitis.mp. or exp lymphocytic colitis/</P>
<P>22. microscopic colitis.mp or exp microscopic colitis/</P>
<P>23. collagenous colitis.mp or exp collagenous colitis/</P>
<P>24. 21 or 22 or 23</P>
<P>25. 20 and 24</P>
<P>= 84</P>
<P>
<B>EMBASE Search Strategy:</B>
</P>
<P>1. random$.tw.</P>
<P>2. factorial$.tw.</P>
<P>3. (crossover$ or cross over$ or cross-over$).tw.</P>
<P>4. placebo$.tw.</P>
<P>5. single blind.mp.</P>
<P>6. double blind.mp.</P>
<P>7. triple blind.mp.</P>
<P>8. (singl$ adj blind$).tw.</P>
<P>9. (double$ adj blind$).tw.</P>
<P>10. (tripl$ adj blind$).tw.</P>
<P>11. assign$.tw.</P>
<P>12. allocat$.tw.</P>
<P>13. crossover procedure/</P>
<P>14. double blind procedure/</P>
<P>15. single blind procedure/</P>
<P>16. triple blind procedure/</P>
<P>17. randomized controlled trial/</P>
<P>18. or/1-17</P>
<P>19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)</P>
<P>20. 18 not 19</P>
<P>21. lymphocytic colitis.mp. or exp lymphocytic colitis/</P>
<P>22. microscopic colitis.mp or exp microscopic colitis/</P>
<P>23. collagenous colitis.mp or exp collagenous colitis/</P>
<P>24. 21 or 22 or 23</P>
<P>25. 20 and 24</P>
<P>
<B>Cochrane Library Search Strategy:</B>
</P>
<P>1. microscopic colitis OR lymphocytic colitis OR collagenous colitis</P>
<P>
<B>Cochrane IBD Specialized Register</B>
</P>
<P>1. microscopic colitis (ab/ti)</P>
<P>2. lymphocytic colitis (ab/ti)</P>
<P>3. collagenous colitis (ab/ti)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;33 reports of 12 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;39 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;204 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;204 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;386 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;4 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;165 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>